

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Nursing, Frailty and Functional Decline in Relation to Older People in Long-term Care Contexts: A Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061303
Article Type:	Protocol
Date Submitted by the Author:	21-Jan-2022
Complete List of Authors:	Flyum, Ida; Karlstad University Faculty of Health Science and Technology, Department of Nursing; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing Gjevjon, Edith; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing Josse-Eklund, Anna; Karlstad University Faculty of Health Science and Technology, Department of Nursing Lærum-Onsager, Ellisiv; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing Borglin, Gunilla; Karlstad University Faculty of Health Science and Technology, Department of Nursing; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing
Keywords:	GERIATRIC MEDICINE, PRIMARY CARE, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

# Nursing, Frailty and Functional Decline in Relation to Older People in Long-term Care Contexts: A Scoping Review Protocol

*Ida Røed Flyum<sup>1,2</sup> RN, MNSc, PhD-candidate, Edith Roth Gjevjon<sup>1</sup> RN, MNSc, PhD, Anna Josse-Eklund<sup>2</sup> RN, DN, PhD, Ellisiv Lærum-Onsager<sup>1</sup> RN, MSc, PhD, Gunilla Borglin<sup>1,2</sup> RN, MSc, PhD, Professor in Nursing*

<sup>1</sup>Lovisenberg Diaconal University College, Department of Bachelor's in Nursing.

Lovisenberggata 15B, NO-0456 Oslo, Norway

<sup>2</sup>Karlstad University, Institute of Health Sciences, Department of Nursing. Universitetsgatan 2, 651 88 Karlstad, Sweden

ORCID:

Ida Røed Flyum: <https://orcid.org/0000-0002-6256-4245>

Edith Roth Gjevjon: <https://orcid.org/0000-0002-9656-522X>

Anna Josse-Eklund: <https://orcid.org/0000-0002-1192-9697>

Ellisiv Lærum-Onsager: <https://orcid.org/0000-0001-9097-6100>

Gunilla Borglin: <https://orcid.org/0000-0002-7934-6949>

**Corresponding author:**

Ida Røed Flyum,

Lovisenberggata 15B,

NO-0456 Oslo, Norway

[Ida.r.flyum@ldh.no](mailto:Ida.r.flyum@ldh.no)

Word count: 3026

## ABSTRACT

**Introduction:** Older people receiving healthcare in long-term care contexts are a heterogeneous population, and they are especially vulnerable to developing frailty and functional decline. Considering the negative effects associated with these conditions and the possibility of preventing them from progressing, it is vital that nurses possess a broad knowledge base about them. The management of care—including detecting and preventing signs and symptoms of frailty and/or functional decline—lies within nurses' range of responsibilities. Such knowledge could guide the development of effective models of care, ensuring continuity and, hence, quality of care. Our objective will be to review published literature on existing models of care targeting frailty and/or functional decline and how these conditions are described by older people themselves, significant others, and nurses in relation to long-term care.

**Methods and analysis:** The review will be conducted in accordance with Arksey and O'Malley's methodological framework. Recent methodological developments will be considered. PubMed, CINAHL and PsycINFO will be searched. Eligibility criteria will be peer-reviewed papers and written in English. All types of study designs will be eligible and included papers will be quality assessed. Older people, significant others, and nurses with experiences from the long-term context will be consulted for the confirmation of the findings. The PRISMA-P checklist for protocols and the PRISMA-ScR checklist were followed in this paper.

**Ethics and dissemination:** Papers eligible for inclusion will be assessed for ethical quality. The findings will be published in an open-access, peer-reviewed journal. Additionally, the findings will be utilised in a research project following the Medical Research Council's framework for developing and evaluating complex interventions. The latter will support us in developing a model of care related to the detection and prevention of frailty and/or functional decline among older people in a long-term care context.

**Registration details:** Open Science Framework, [10.17605/OSF.IO/FNHSA](https://doi.org/10.17605/OSF.IO/FNHSA).

**Strengths and limitations of this study:**

- Designing and reporting the protocol and upcoming scoping review in accordance with the PRISMA checklists will ensure the transparency, reliability and rigour of the review.
- The support of an information specialist in developing a comprehensive search strategy will ensure a higher probability of identifying eligible papers.
- Using a review team of five individuals will ensure independent assessment by two reviewers in all stages, as well as the opportunity to consult with a third person if necessary.
- Adopting a joint strategy of quality assessment and comprehensive overview may contribute to both identifying the gaps in the literature, as well as increasing the uptake and relevance of the results for practice and policy makers.
- Not including stakeholders in the conception and designing of this review might be a limitation.

## INTRODUCTION

Considering the potential adverse health outcomes of frailty and functional decline,<sup>1 2</sup> as well as the potential reversibility of these conditions,<sup>3</sup> there is an undeniable need for effective models of care for the early detection and prevention of frailty and functional decline among older people in long-term care contexts (e.g., home healthcare, sheltered housing and nursing home contexts).<sup>4</sup> Preventing frailty and functional decline as a part of a healthy ageing strategy is a globally important aim and has been promoted by both the European Commission and World Health organisation (WHO).<sup>5 6</sup> Despite their global attention, both conditions are repeatedly described as closely related, and the terms are often used interchangeably.<sup>7 8</sup> The nature of their relationship has been debated, even though the consensus appears to be that frailty predicts functional decline and disability.<sup>3 9</sup> Our upcoming scoping review will depart from the idea of such a relationship.

It is well known that we live longer and, hence, are at an increased risk of multimorbidity, polypharmacy and the presentation of complex symptoms.<sup>10</sup> This indicates that the number of older people with frailty and at risk of functional decline<sup>7 10 11</sup> also is likely to substantially increase. The prevalence of frailty tends to vary, which might be because of the use of numerous definitions and screening instruments but also because frailty tends to increase with age.<sup>12</sup> Among community-dwelling older people (60+), the prevalence of frailty has been estimated to be between 2.6% and 60%<sup>13 14</sup> and for nursing home patients between 19% and 75.6%.<sup>14 15</sup> Frailty has also been associated with increased healthcare-related costs.<sup>16</sup> The early detection and preventative healthcare measures targeting these two conditions in long-term care contexts seems vital both for the healthcare offered and the quality of care for older patients. Unfortunately, such measures are challenging for several reasons.

First, older people receiving healthcare services in long-term care contexts are a heterogeneous population; they range from being relatively independent and in need of low-intensity care to being dependent on a range of activities of daily living (ADL) and in need of high intensity care.<sup>10</sup> Furthermore, it is fair to assume that through, for example, informal caregivers, these individuals' deteriorations might be compensated for and delayed over a longer period of time, thereby masking their actual care needs. This complex composition within both the population and the individuals themselves – masking actual care needs – increases the risk of adverse health outcomes because of the difficulties to detect the conditions.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Second, there is a growing number of older people ageing in place—that is, staying in their own homes.<sup>17</sup> This trend is believed to contribute to appropriate care at a lower cost compared with institutionalised care.<sup>18 19</sup> Furthermore, according to Boland, et al.<sup>20</sup> there is insufficient evidence related to health-related outcomes to recommend either institutionalised care or home healthcare. Emphasising the preference of the older person when considering moving the locations of care should be taken into account. Research implies that most older people value their independence and prefer to remain in a familiar environment where they feel like they belong.<sup>17</sup> Stressing the importance of detecting and preventing conditions such as frailty and/or functional decline early on in this population. This might result in positive implications when it comes to their possibility for healthy ageing<sup>5 21</sup> and contribute to more older people having the choice of ageing in place.<sup>17 21 22</sup> However, it has been documented that long-term care services experience limitations related to the following: time with patients, number of healthcare staff with adequate competence, collaboration with other professions, guidelines and protocols for care, high rates of sick leave, part-time workers and nurse retention.<sup>22-24</sup> This might increase the risk of nursing staff (e.g., registered nurses, registered practical nurses, licensed practical nurses, and nursing assistants/aides)<sup>25</sup>—hereinafter referred to as nurses—being forced to ration care.<sup>26</sup> This may result in patient monitoring being less prioritised and a further rationing of care that might lead to the signs and symptoms related to frailty and/or functional decline going unobserved. This can risk both patient safety and satisfaction.<sup>27</sup>

Third, a prerequisite for detecting and preventing frailty and/or functional decline is a clear definition and understanding of the concepts, both medically and clinically. A number of definitions have been proposed, yet no consensus exists.<sup>8 28</sup> In the upcoming scoping review, frailty will be understood in accordance with Clegg et al.'s<sup>29</sup> description as '*a state of vulnerability to poor resolution of homeostasis after a stressor event and is a consequence of cumulative decline in many physiological systems during a lifetime*' (p. 1). A critical point in the degenerative processes is reached where the homeostatic mechanisms are no longer sufficient. This results in vulnerability, that is, a seemingly small incidence (new drug or a 'minor' infection), having a disproportionate effect on the individual's health.<sup>29</sup> This then increases the risk of adverse health outcomes such as falls, hospitalisation, disability and death.<sup>1</sup> Furthermore, the dependency in ADLs in people with frailty may fluctuate substantially. This is often referred to as 'unstable disability',<sup>29</sup> and we postulate that such fluctuating disability could be understood as functional decline.

1  
2  
3 For the upcoming review, functional decline will be defined as a new loss of independence in  
4 self-care activities or as a deterioration in self-care skills, here as measured on an ADL scale  
5 (e.g., bathing, dressing, transferring from bed to chair, using the toilet, etc.) and/or on an  
6 instrumental activities of daily living (IADL) scale (e.g., shopping, housekeeping, preparing  
7 meals, etc.).<sup>30,31</sup> Functional decline among older people can also result in compromises beyond  
8 ADL for example physical problems such as falls and malnutrition and psychosocial problems  
9 such as depression and delirium.<sup>32</sup> According to Hébert<sup>33</sup> functional decline may manifest  
10 subacutely or acutely. Subacute functional decline slowly develops over time and is more  
11 difficult to detect than acute functional decline, particularly if the patients are not screened for  
12 physical or mental capacity changes. Usually, this is caused by chronic disease or a new,  
13 undetected disease, but it may also arise because of polypharmacy, cognitive decline or a  
14 psychiatric condition. Acute functional decline often manifests in a couple of days to a week  
15 and requires emergent medical attention and hospitalisation. It can be caused by an acute  
16 incident (e.g., infection, fall or stroke), malfunction in compensatory mechanisms of a chronic  
17 condition or a psychological crisis (e.g., death of a significant other or hospital admission).

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 Among healthcare professionals, nurses are the largest professional group. They are often the  
32 first point of contact, and they are also the group that spends the most time with the patients.  
33 Thus, the management of care, including detecting and preventing the signs and symptoms of  
34 frailty and/or functional decline, lies both within their remit and range of responsibilities.  
35 Despite this, we have not been able to identify any published reviews summarising the evidence  
36 within this field. Instead, recent reviews have focused on areas such as the effect of  
37 interventions<sup>34-37</sup> and screening tools.<sup>38-40</sup> Furthermore, we might argue that to develop effective  
38 models of care related to these conditions, it is critical to understand how frailty and functional  
39 decline might be described beyond our medical understanding and by important stakeholders.

40  
41  
42  
43  
44  
45  
46  
47  
48 Additionally, nurses are expected to provide a diverse range of healthcare services, and one of  
49 their functions is to assess, diagnose, intervene and evaluate a patient's personal health needs.<sup>41</sup>  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

as how these two conditions are described and understood by older people themselves, their significant others, and nurses in relation to long-term care.

## METHOD AND ANALYSIS

The upcoming scoping review will be conducted in accordance with Arksey and O'Malley's<sup>43</sup> methodological frameworks for conducting scoping studies. Additionally, methodological developments will be considered, that is, Levac, et al.<sup>44</sup> and Daudt, et al.<sup>45</sup> Scoping reviews are preferred when the research area has not previously been comprehensively reviewed and is of a complex nature.<sup>43</sup> The included papers will undergo ethical and critical appraisal,<sup>44 46 47</sup> relevant data will be extracted,<sup>44 48</sup> and data answering the review questions will be analysed by content analysis.<sup>49</sup>

This protocol will utilise the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) checklist,<sup>50</sup> as well as the PRISMA-P checklist for reporting protocols (Supplementary file 1-2),<sup>51</sup> which is recommended for scoping reviews and systematic reviews.<sup>52</sup> As recommended, the upcoming review is registered in the Open Science Framework (OSF) (registration number [10.17605/OSF.IO/FNHSA](https://doi.org/10.17605/OSF.IO/FNHSA). Registered and last updated on 30 June 2021).

### Stage 1: Identifying the research question

In accordance with Arksey and O'Malley<sup>43</sup> tentative and broad research questions were formulated following the PICoS (Population, Phenomenon of Interest, Context and Study design) framework (Table 1). In accordance with the iterative approach of a scoping review, the tentative research questions may be reformulated as we gain familiarity with the research area.<sup>43</sup>

- What models of care, frameworks and approaches targeting the detection and prevention of frailty and/or functional decline among older people are described in long-term care contexts?
- How is the concept of frailty described and understood by older people, their significant others, and nurses in long-term care contexts?
- How is the concept of functional decline described and understood by older people, their significant others, and nurses in long-term care contexts?

Furthermore, subquestions will encompass the following: By whom are the questions in the literature answered, in what specific contexts, in relation to whom or what? Which research designs have been utilised? How is the methodological quality appraised?

**Table 1.** PICO framework for determination of eligibility of review questions

Criteria	Determinants
<b>Population</b>	<ul style="list-style-type: none"> <li>- Older people (65+ years)</li> <li>- Significant others</li> <li>- Nurses</li> </ul>
<b>Phenomenon of Interest</b>	<ul style="list-style-type: none"> <li>- Descriptions of models of care, frameworks and approaches targeting detection and prevention of frailty and/or functional decline among older people</li> <li>- Descriptions of frailty and/or functional decline among older people</li> </ul>
<b>Context</b>	<ul style="list-style-type: none"> <li>- Long-term care, e.g., home healthcare, sheltered housing and nursing homes</li> </ul>
<b>Study design</b>	<ul style="list-style-type: none"> <li>- All study designs</li> </ul>

## Stage 2: Identifying relevant studies

Systematic searches will be conducted in PubMed, CINAHL and PsycINFO. These databases cover the majority of the published, peer-reviewed health service research. The search strategies will be constructed following the PICO categories and will be tailored to each database. To achieve a comprehensive search strategy with sensitivity and specificity, we will include both controlled subject headings such as MeSH,<sup>53</sup> as well as keywords and synonyms. No time limitation will be implemented because of the lack of earlier reviews and the aim to comprehensively map the area of interest.<sup>43</sup> A preliminary search strategy was constructed for PubMed in collaboration with an information specialist at Karlstad University (Supplementary File 3, last updated on 19 January 2022). Additionally, the reference lists of all the included papers will be searched.<sup>43 53 54</sup> The final search strategy for each database will be checked by an independent information specialist using the PRESS checklist.<sup>53</sup> To ensure transparency in the iterative process, the first author will keep a logbook throughout the entire project to track amendments from this protocol and other decisions made, including the rationale.<sup>54 55</sup> Considering what types of research will most likely be relevant for answering our research questions, as well as the time and resources needed searching for grey literature,<sup>54</sup> we have decided to include only published, peer-reviewed research.

### Stage 3: Study selection

To ensure consistency, reliability and validity in the selection process, eligibility criteria will be constructed.<sup>44</sup> A tentative summary of the eligibility criteria is described below. Still, in accordance with the iterative process, the eligibility criteria might be refined as familiarity with the field increases and can then be applied to all citations post hoc.<sup>43</sup>

Using the eligibility criteria, two independent reviewers will assess the relevance of all titles and abstracts in the search results. The full text of the relevant papers, as well as those where relevance is unclear, will be assessed for inclusion<sup>43</sup> by two reviewers.<sup>44 45</sup> Meetings will be held regularly to address any uncertainties.<sup>44</sup> Disagreements will be resolved through discussion and, if necessary, consultation with a third reviewer. The selection process will be documented using the PRISMA flowchart<sup>56</sup> (Figure 1). The data programme Rayyan will be utilised using the option 'blind on' to ensure an independent review.<sup>57</sup>

**Insert --- Figure 1. about here ---**

The eligibility criteria relate to the categories in PICoS, as well as the research type, language and ethical considerations. The population will be limited to older people, their significant others, and nurses. Older people will be defined as all people over the age of 65 years, considering that this is a standard cut-off for older people in most research and databases today. Because there exists no consensus definition of frailty or functional decline, we will use the definitions presented in the introduction of this protocol as the inclusion criteria. The context will be defined as long-term care contexts, for example, home healthcare, sheltered housing and nursing homes. All study designs will be included. Because the aim of the review is to summarise evidence from published, peer-reviewed research, we will exclude research types not complying with these parameters, such as letters to the editor and discussion papers. Considering time and resources, we will only include papers that do not need translation, that is, those in English. There is a rising appreciation of the contribution that ethical quality assessment in reviews may have on sustainable and ethical research.<sup>46 47</sup> To contribute to this work, we have constructed a tentative list of the ethical requirements for the included papers, as influenced by Weingarten, et al.<sup>46</sup> (Table 2). Depending on the total number of eligible papers and the overall methodological and ethical quality, a decision regarding excluding papers of subpar standards will be made.

**Table 2.** Ethical requirements

Was the study approved by an ethical research committee?	Yes/No
Was informed consent retrieved from all participants?	Yes/No
Were the personal data/transcriptions/recordings properly managed, stored and disposed off?	Yes/No
Was the relevance of the study clearly justified?	Yes/No
Was any conflict of interests or funding declared?	Yes/No

**Stage 4: Charting the data**

A data charting form will be utilised to facilitate the systematic charting of data from each paper (Box 1). Two reviewers will independently pilot this form on the first five to ten relevant papers. If necessary, the form will be augmented.<sup>44 48</sup> When finalised, two independent reviewers will apply the form to all relevant papers. Disagreements will be resolved by discussion with the review team, if needed.

**Box. 1** Tentative data charting items

<b>Full reference</b>
<b>Aim</b>
<b>Population</b>
<b>Phenomenon of Interest</b>
<b>Country and Context</b>
<b>Study design</b>
<b>Data collection method</b>
<b>Data analysis</b>
<b>Relevant findings</b>
<b>Quality assessment</b>

Quality appraisal in scoping reviews is a topic of debate, with researchers both for<sup>44 45 58</sup> and against it.<sup>43 48</sup> Despite this all the included papers will be quality assessed but included regardless of the results. No weighting of the evidence will be done;<sup>43</sup> rather, a quality assessment will be utilised to identify potential gaps in the literature related to high-quality research.<sup>44</sup> The quality assessment will be conducted by two independent reviewers using the checklists from the Critical Appraisal Skills Programme (CASP).<sup>59</sup> For mixed method studies, the mixed method appraisal tool will be applied.<sup>60</sup>

### **Stage 5: Collating, summarising and reporting the results**

The charted data will be presented both schematically and narratively. Numerical analysis of the quantitative data will be descriptive and focus on the nature, extent and distribution of the data. How the results are presented will depend on the findings (e.g., tables, chart, figures).<sup>48</sup> As recommended by Levac, et al.<sup>44</sup> qualitative content analysis with a focus on the manifest content will be implemented.<sup>49</sup> Using a descriptive approach and focusing on manifest content entails a very low degree of interpretation.<sup>61</sup> This is in accordance with the aim of summarising—not synthesising—evidence in a scoping review.<sup>43</sup> Additionally, the PAGER framework will be considered.<sup>62</sup> Two reviewers will be responsible for this stage, and regular meetings will be conducted with the whole review team.

### **Stage 6: Consulting stakeholders and experts**

Consulting with different experts and stakeholders will be done through different parts of the review to validate the entire process and end results. First, through consulting with the information specialist, the search strategies will be validated.<sup>55</sup> Second, to investigate the concordance between the review results and views of relevant stakeholders, we will present the tentative results to a discussion group<sup>63</sup> consisting of older people, their significant others and nurses. If relevant, we will adjust the presentation of the results or the categories or remark on potential deficiencies in the data from the included papers. This will assist in assessing if the results are relevant for the stakeholders.<sup>44</sup>

### **Patient and public involvement**

No patients are involved in the conception or design of the upcoming review, but both patients, their significant others and healthcare professionals will be involved in validating the review results through discussion groups.

## **ETHICS AND DISSEMINATION**

Despite reviews being excluded from ethical assessment by ethical review authorities,<sup>64-66</sup> the need for ethical considerations when conducting reviews has been highlighted by Vergnes, et al.<sup>47</sup> and Weingarten, et al.<sup>46</sup> We will contribute to this by considering the ethical standards of all eligible papers.

1  
2  
3 Furthermore, to ensure an effective literature review, as well as avoid research waste,<sup>67</sup> we have  
4 conducted a thorough exploratory search to assess the need for the upcoming review. The  
5 ethical importance of writing this protocol should also be mentioned because protocols  
6 alongside the precise logging of amendments in the final review manuscript are an important  
7 part of making our review transparent to criticism.  
8  
9  
10  
11  
12

13 As part of the scoping review design, disseminating the results will begin through consultation  
14 with stakeholders and experts. Furthermore, the scoping review will be published in a peer-  
15 reviewed, open-access journal. Tentatively, the findings will be reported by early autumn 2022.  
16 Additionally, the findings will be utilised in a research project following the Medical Research  
17 Council's framework for developing and evaluating complex interventions<sup>68</sup> to inform the  
18 development of a model of care related to the detection and prevention of frailty and/or  
19 functional decline among older people in a long-term care context.  
20  
21  
22  
23  
24  
25  
26

## 27 **ACKNOWLEDGEMENTS**

28 We would like to thank XXX, Information Specialist at Karlstad University, for her  
29 contribution to the search strategies presented in this protocol.  
30  
31  
32

## 33 **AUTHORS' CONTRIBUTIONS**

34 IRF, GB, ERG, AJ-E and EL-O were responsible for the study's inception and design. IRF was  
35 responsible for drafting the first version of the manuscript. GB, ERG, AJO and ELO were  
36 responsible for the critical revision of the paper and for adding important intellectual content.  
37 GB supervised the study. All authors read and approved the final manuscript.  
38  
39  
40  
41  
42  
43

## 44 **FUNDING STATEMENT**

45 This research received no specific grant from any funding agency in the public, commercial  
46 or not-for-profit sectors.  
47  
48  
49  
50

## 51 **COMPETING INTERESTS STATEMENT**

52 The authors of this scoping review protocol declare no competing interests in connection with  
53 this manuscript.  
54  
55  
56  
57  
58  
59  
60

## LICENCE STATEMENT

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

## REFERENCES

1. Fried LP, Tangen CM, Walston J, et al. Frailty in Older Adults: Evidence for a Phenotype. *The Journals of Gerontology: Series A* 2001;56(3):M146-M57. doi: <https://doi.org/10.1093/gerona/56.3.M146>
2. Vermeiren S, Vella-Azzopardi R, Beckwée D, et al. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. *JAMDA* 2016;17(12):1163.e1-63.e17. doi: <https://doi.org/10.1016/j.jamda.2016.09.010>
3. Sezgin D, Liew A, O'Donovan MR, et al. Pre-frailty as a multi-dimensional construct: A systematic review of definitions in the scientific literature. *Geriatric Nursing* 2020;41(2):139-46. doi: <https://doi.org/10.1016/j.gerinurse.2019.08.004>
4. National Institute on Ageing. Enabling the Future Provision of Long-Term Care in Canada. Toronto, 2019.
5. World health organization. Decade of Healthy Ageing 2020-2030, 2020.
6. Cano A, Dargent G, Carriazo A, et al. Tackling frailty and functional decline: Background of the action group A3 of the European innovation partnership for active and healthy ageing. *Maturitas* 2018;115:69-73. doi: <https://doi.org/10.1016/j.maturitas.2018.06.009>
7. Beaton K, McEvoy C, Grimmer K. Identifying indicators of early functional decline in community-dwelling older people: A review. *Geriatrics & Gerontology International* 2014;15(2):133-40. doi: <https://doi.org/10.1111/ggi.12379>
8. Sezgin D, O'Donovan M, Cornally N, et al. Defining frailty for healthcare practice and research: A qualitative systematic review with thematic analysis. *International Journal of Nursing Studies* 2019;92:16-26. doi: <https://doi.org/10.1016/j.ijnurstu.2018.12.014>
9. Church S, Rogers E, Rockwood K, et al. A scoping review of the Clinical Frailty Scale. *BMC Geriatrics* 2020;20:1-18. doi: <https://doi.org/10.1186/s12877-020-01801-7>
10. Roller-Wirnsberger R, Singler K, Polidori MC. Learning Geriatric Medicine: A Study Guide for Medical Students: Springer International Publishing AG 2018.
11. Fried LP, Ferrucci L, Darer J, et al. Untangling the Concepts of Disability, Frailty, and Comorbidity: Implications for Improved Targeting and Care. *The Journals of Gerontology: Series A* 2004;59(3):M255-M63. doi: <https://doi.org/10.1093/gerona/59.3.M255>


12. Kehler DS, Ferguson T, Stammers AN, et al. Prevalence of frailty in Canadians 18–79 years old in the Canadian Health Measures Survey. *BMC Geriatrics* 2017;17 doi: <https://doi.org/10.1186/s12877-017-0423-6>
13. Collard RM, Boter H, Schoevers RA, et al. Prevalence of Frailty in Community-Dwelling Older Persons: A Systematic Review. *Journal of the American Geriatrics Society* 2012;60(8):1487-92. doi: <https://doi.org/10.1111/j.1532-5415.2012.04054.x>
14. O'Caioimh R, Galluzzo L, Rodríguez-Laso Á, et al. Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis. *Ann Ist Super Sanità* 2018;54(3):226-38. doi: [http://dx.doi.org/10.4415/ANN\\_18\\_03\\_10](http://dx.doi.org/10.4415/ANN_18_03_10)
15. Kojima G. Prevalence of Frailty in Nursing Homes: A Systematic Review and Meta-Analysis. *JAMDA* 2015;16(11):940-45. doi: <https://doi.org/10.1016/j.jamda.2015.06.025>
16. Kojima G. Increased healthcare costs associated with frailty among community-dwelling older people: A systematic review and meta-analysis. *Arch Gerontol Geriatr* 2019;84 doi: <https://doi.org/10.1016/j.archger.2019.06.003>
17. Pani-Harreman KE, Bours GJJW, Zander I, et al. Definitions, key themes and aspects of 'ageing in place': a scoping review. *Ageing and society* 2021;41:2026-59. doi: <http://dx.doi.org/10.1017/S0144686X20000094>
18. Genet N, Boerma W, Kroneman M, et al. Home care across Europe: Current structure and future challenges. *European Observatory on Health Systems and Policies* 2012
19. Horner B, Boldy DP. The benefit and burden of "ageing-in-place" in an aged care community. *Aust Health Rev* 2008;32(2):356-65. doi: <http://dx.doi.org/10.1071/ah080356>
20. Boland L, Légaré F, Perez MMB, et al. Impact of home care versus alternative locations of care on elder health outcomes: an overview of systematic reviews. *BMC geriatrics* 2017;17:1-15. doi: <http://dx.doi.org/10.1186/s12877-016-0395-y>
21. Norwegian Ministry of Health and Care Services. A full life - all your life: A Quality Reform for Older Persons. 2019
22. Spasova S, Baeten R, Coster S, et al. Challenges in long-term care in Europe - A study of national policies 2018. Brussels: European Commission: European Social Policy Network (ESPN), 2018.
23. Valizadeh L, Zamanzadeh V, Saber S, et al. Challenges and Barriers Faced by Home Care Centers: An Integrative Review. *Med Surg Nurs J* 2019 doi: <https://10.5812/msnj.83486>
24. OECD. Health at a Glance 2021: OECD Indicators 2021.
25. Chu CH, McGilton KS, Spilsbury K, et al. Strengthening International Research in Long-Term Care: Recommended Common Data Elements to Support Clinical Staff Training. *Gerontology & Geriatric Medicine* 2021;7:1-17. doi: <https://doi.org/10.1177/2333721421999312>
26. Kalánková D, Žiaková K, Kuručová R. Approaches to understanding the phenomenon of missed/rationed/unfinished care - a literature review. *Cent Eur J Nurs Midw* 2019;10(1):1005-16. doi: <https://doi.org/10.15452/CEJNM.2019.10.0007>
27. Kalánková D, Kirwan M, Bartoníčková D, et al. Missed, rationed or unfinished nursing care: A scoping review of patient outcomes. *J Nurs Manag* 2020;28(8):1783-97. doi: <https://doi.org/10.1111/jonm.12978>
28. Junius-Walker U, Onder G, Soleymani D, et al. The essence of frailty: A systematic review and qualitative synthesis on frailty concepts and definitions. *European Journal of Internal Medicine* 2018;56:3-10. doi: <https://doi.org/10.1016/j.ejim.2018.04.023>

29. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *The Lancet* 2013;381(9868):752-62. doi: [https://doi.org/10.1016/S0140-6736\(12\)62167-9](https://doi.org/10.1016/S0140-6736(12)62167-9)
30. Fortinsky RH, Covinsky KE, Palmer RM, et al. Effects of functional status changes before and during hospitalization on nursing home admission of older adults. *J Gerontol A Biol Sci Med Sci* 1999;54(10):M521-6. doi: <https://doi.org/10.1093/gerona/54.10.m521>
31. Hébert R, Brayne C, Spiegelhalter D. Factors Associated with Functional Decline and Improvement in a Very Elderly Community-dwelling Population. *Am J Epidemiol* 1999;150(5):501-10. doi: <https://doi.org/10.1093/oxfordjournals.aje.a010039>
32. de Vos AJBM, Asmus-Szepesi KJE, Bakker TJEM, et al. Integrated approach to prevent functional decline in hospitalized elderly: the Prevention and Reactivation Care Program (PReCaP). *BMC Geriatrics* 2012;12 doi: <https://doi.org/10.1186/1471-2318-12-7>
33. Hébert R. Functional decline in old age. *Can Med Assoc J* 1997;157(8):1037-45.
34. Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: a systematic review. *JBIM Database System Rev Implement Rep* 2018;16(1):140-232. doi: <https://doi.org/10.11124/JBISRIR-2017-003382>
35. Travers J, Romero-Ortuno R, Bailey J, et al. Delaying and reversing frailty: a systematic review of primary care interventions. *British Journal of General Practice* 2019;69(678):e61-e69. doi: <http://doi.org/10.3399/bjgp18X700241>
36. Verstraten CCJMM, Metzelthin SF, Schoonhoven L, et al. Optimizing patients' functional status during daily nursing care interventions: A systematic review. *Research in Nursing & Health* 2020;43(5):478-88. doi: <https://doi.org/10.1002/nur.22063>
37. Mareschal J, Genton L, Collet T-H, et al. Nutritional Intervention to Prevent the Functional Decline in Community-Dwelling Older Adults: A Systematic Review. *Nutrients* 2020;12(9):1-21.
38. Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Predicting risk and outcomes for frail older adults: an umbrella review of frailty screening tools. *JBIM Database System Rev Implement Rep* 2017;15(4):1154-208. doi: <https://doi.org/10.11124/jbisrir-2016-003018>
39. Faller JW, Pereira DdN, de Souza S, et al. Instruments for the detection of frailty syndrome in older adults: A systematic review. *PLOS ONE* 2019;14(4):e0216166. doi: <https://doi.org/10.1371/journal.pone.0216166>
40. Roedel KJ, Wilson LS, Fine J. A systematic review and comparison of functional assessments of community-dwelling elderly patients. *J Am Assoc Nurse Pract* 2016;28(3):160-9. doi: <https://doi.org/10.1002/2327-6924.12273>
41. Henderson V. *The Nature of Nursing a Definition and its Implications for Practice, Research, and Education*: Macmillan 1966.
42. Richards DA, Borglin G. 'Shitty nursing' – The new normal? *International Journal of Nursing Studies* 2019;91:148-52. doi: <https://doi.org/10.1016/j.ijnurstu.2018.12.018>
43. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International Journal of Social Research Methodology* 2005;8(1):19-32. doi: <https://doi.org/10.1080/1364557032000119616>
44. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implementation Sci* 2010;5:69. doi: <https://doi.org/10.1186/1748-5908-5-69>
45. Daudt HML, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team's experience with Arksey and O'Malley's framework. *BMC Medical Research Methodology* 2013;13:48. doi: <https://doi.org/10.1186/1471-2288-13-48>

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
46. Weingarten MA, Paul M, Leibovici L. Assessing ethics of trials in systematic reviews. *BMJ* 2004;328:1013-14. doi: <https://doi.org/10.1136/bmj.328.7446.1013>
  47. Vergnes J-N, Marchal-Sixou C, Nabet C, et al. Ethics in systematic reviews. *J Med Ethics* 2010;36(12):771-74. doi: <https://doi.org/10.1136/jme.2010.039941>
  48. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth* 2020;18(10):2119-26. doi: <https://doi.org/10.11124/JBIES-20-00167>
  49. Elo S, Kyngäs H. The qualitative content analysis process. *Journal of Advanced Nursing* 2008;62(1):107-15. doi: <https://doi.org/10.1111/j.1365-2648.2007.04569.x>
  50. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR) : Checklist and Explanation. *Ann Intern Med* 2018;169:467-73. doi: <https://doi.org/10.7326/M18-0850>
  51. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647. doi: <https://doi.org/10.1136/bmj.g7647>
  52. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015;4:1. doi: <https://doi.org/10.1186/2046-4053-4-1>
  53. Bramer WM, de Jonge GB, Rethlefsen ML, et al. A systematic approach to searching: an efficient and complete method to develop literature searches. *J Med Libr Assoc* 2018;106(4):531-41. doi: <https://doi.org/10.5195/jmla.2018.283>
  54. Booth A. Searching for qualitative research for inclusion in systematic reviews: a structured methodological review. *Systematic Reviews* 2016;5:74. doi: <https://doi.org/10.1186/s13643-016-0249-x>
  55. Pollock D, Davies EL, Peters MDJ, et al. Undertaking a scoping review: A practical guide for nursing and midwifery students, clinicians, researchers, and academics. *Journal of Advanced Nursing* 2021;77(4):2102-13. doi: <https://doi.org/10.1111/jan.14743>
  56. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: <https://doi.org/10.1136/bmj.n71>
  57. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. *Systematic Reviews* 2016;5:210. doi: <https://doi.org/10.1186/s13643-016-0384-4>
  58. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. *Health Information & Libraries Journal* 2009;26(2):91-108. doi: <https://doi.org/10.1111/j.1471-1842.2009.00848.x>
  59. Critical Appraisal Skills Programme. CASP Checklists n.d. [Available from: <https://casp-uk.net/casp-tools-checklists/>]
  60. Hong QN, Pluye P, Fàbregues S, et al. Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study. *Journal of Clinical Epidemiology* 2019;111:49-59. doi: <https://doi.org/10.1016/j.jclinepi.2019.03.008>
  61. Lindgren B-M, Lundman B, Graneheim UH. Abstraction and interpretation during the qualitative content analysis process. *Int J Nurs Stud* 2020;108:103632-32. doi: <https://doi.org/10.1016/j.ijnurstu.2020.103632>
  62. Bradbury-Jones C, Aveyard H, Herber OR, et al. Scoping reviews: the PAGER framework for improving the quality of reporting. *International Journal of Social Research Methodology* 2021:1-14. doi: <https://doi.org/10.1080/13645579.2021.1899596>

- 1  
2  
3 63. Doria N, Condran B, Boulos L, et al. Sharpening the focus: differentiating between focus  
4 groups for patient engagement vs. qualitative research. *Research Involvement and*  
5 *Engagement* 2018; 4(19).  
6  
7 64. Utbildningsdepartementet. Lag (2003:460) om etikprövning av forskning som avser  
8 människor, 2003.  
9  
10 65. Helseforskningsloven. Lov om medisinsk og helsefaglig forskning 2008.  
11  
12 66. Norwegian centre for research data. n.d. [Available from: <https://www.nsd.no>  
13  
14 67. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research  
15 evidence. *Lancet* 2009;374(9683):86-89. doi: [https://doi.org/10.1016-](https://doi.org/10.1016/S0140-6736(09)60329-9)  
16 [6736\(09\)60329-9](https://doi.org/10.1016/S0140-6736(09)60329-9)  
17  
18 68. Skivington K, Matthews L, Simpson SA, et al. A new framework for developing and  
19 evaluating complex interventions: update of Medical Research Council guidance. *BMJ*  
20 2021;374 doi: <http://10.1136/bmj.n2061>  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. PRISMA-flowchart: Overview of the study selection process



Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

## SUPPLEMENTARY FILE 1

## Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
<b>TITLE</b>			
Title	1	Identify the report as a scoping review.	Title page
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	1
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	3-6
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	5-6
<b>METHODS</b>			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	6

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	8
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Supplementary File 3
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	Box 1

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	9
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	10
<b>RESULTS</b>			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Not applicable for the protocol
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Not applicable for the protocol
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not applicable for the protocol
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Not applicable for the protocol
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Not applicable for the protocol
<b>DISCUSSION</b>			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of	Not applicable for the protocol

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
		evidence available), link to the review questions and objectives, and consider the relevance to key groups.	
Limitations	20	Discuss the limitations of the scoping review process.	Not applicable for the protocol
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	Not applicable for the protocol
<b>FUNDING</b>			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	11

JBIG = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

\* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467-473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850)

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Erasmushogeschool

## SUPPLEMENTARY FILE 2

### PRISMA-P 2015 Checklist

This checklist was retrieved by the authors of this protocol from the PRISMA web page, and is an adapted version of Table 3 in Moher, et al.<sup>52</sup>: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
<b>ADMINISTRATIVE INFORMATION</b>					
<b>Title</b>					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Title page
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Registration</b>	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1 and 6
<b>Authors</b>					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Title page
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11
<b>Amendments</b>	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7
<b>Support</b>					
Sources	5a	Indicate sources of financial or other support for the review	<input type="checkbox"/>	<input checked="" type="checkbox"/>	11

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
					No funders/sponsors
Sponsor	5b	Provide name for the review funder and/or sponsor	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Not applicable
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Not applicable
<b>INTRODUCTION</b>					
Rationale	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	3-6
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	6
<b>METHODS</b>					
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Supplementary File 3
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8

1 by copyright, including for uses related to text and data mining, AI training and similar technologies.  
 Erasmushogeschool  
 36/bmjopen-2022-061303 on 23 August 2022. Downloaded from <http://bmjopen.bmj.com/> on May 15, 2025 at Department GEZ-LTA  
 Department GEZ-LTA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
<b>Data items</b>	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Box 1
<b>Outcomes and prioritization</b>	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Box 1
<b>Risk of bias in individual studies</b>	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
<b>DATA</b>					
<b>Synthesis</b>	15a	Describe criteria under which study data will be quantitatively synthesized	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
<b>Meta-bias(es)</b>	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Confidence in cumulative evidence</b>	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

## SUPPLEMENTARY FILE 3

Tentative search strategy: PubMed

Last updated on: 19.01.22

**Question 2:** How is the concept of frailty described and understood by older people, their significant others, and nurses in long-term care contexts?

PubMed	Search block: Older people (P)		19. Jan 2022
Search #	Query	Search string	Results
#1	Aged	"aged"[MeSH Terms] OR "aged"[All Fields]	5,765,926
#2	Elderly	"aged"[MeSH Terms] OR "aged"[All Fields] OR "elderly"[All Fields] OR "elderlies"[All Fields] OR "elderly s"[All Fields] OR "elderlys"[All Fields]	5,823,455
#3	Older	"older"[All Fields] OR "olders"[All Fields]	496,898
#4	Combination:	<b>#1 OR #2 OR #3</b>	5,978,243

PubMed	Search block: Significant others (P)		19. Jan 2022
Search #	Query	Search string	Results
#5	Significant others	"significant"[All Fields] AND "other*"[All Fields]	763,016
#6	Informal caregivers	"caregivers"[MeSH Terms] OR "caregiver*"[All Fields] OR ("informal"[All Fields] AND "caregiver*"[All Fields])	92,958
#7	Family	"family"[MeSH Terms] OR "family"[All Fields] OR "families"[All Fields] OR "family s"[All Fields] OR "familys"[All Fields]	1,542,673
#8	Relatives	"relative"[All Fields] OR "relatives"[All Fields] OR "relative s"[All Fields]	984,365
#9	Family caregivers	"caregivers"[MeSH Terms] OR "caregiver*"[All Fields] OR ("family"[All Fields] AND "caregiver*"[All Fields])	92,958
#10	Spouses	"spouse s"[All Fields] OR "spouses"[MeSH Terms] OR "spouses"[All Fields] OR "spouse"[All Fields]	34,339
#11	Husbands	"husband s"[All Fields] OR "husband"[All Fields] OR "husbands"[All Fields]	14,379
#12	Wives	"wife"[All Fields] OR "wives"[All Fields] OR "wife s"[All Fields]	11,491
#13	Next-of-kin	"Next-of-kin"[All Fields]	1,920
#14	Combination:	<b>#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13</b>	3,174,444

PubMed	Search block: Nursing staff (P)		19. Jan 2022
Search #	Query	Search string	Results
#15	Nurse	"nurse s"[All Fields] OR "nurses"[MeSH Terms] OR "nurses"[All Fields] OR "nurse"[All Fields] OR "nurses s"[All Fields]	408,405

#16	Nursing personnel	"nursing staff"[MeSH Terms] OR ("nursing"[All Fields] AND "staff"[All Fields]) OR "nursing staff"[All Fields] OR ("nursing"[All Fields] AND "personnel"[All Fields]) OR "nursing personnel"[All Fields] OR "nurses"[MeSH Terms] OR "nurses"[All Fields] OR ("nursing"[All Fields] AND "personnel"[All Fields])	365,108
#17	Healthcare assistants	"allied health personnel"[MeSH Terms] OR ("allied"[All Fields] AND "health"[All Fields] AND "personnel"[All Fields]) OR "allied health personnel"[All Fields] OR ("healthcare"[All Fields] AND "assistants"[All Fields]) OR "healthcare assistants"[All Fields]	56,879
#18	Healthcare aides	("delivery of health care"[MeSH Terms] OR ("delivery"[All Fields] AND "health"[All Fields] AND "care"[All Fields]) OR "delivery of health care"[All Fields] OR "healthcare"[All Fields] OR "healthcare s"[All Fields] OR "healthcares"[All Fields]) AND "aides"[All Fields]	1,248
#19	Nursing assistants	"nursing assistants"[MeSH Terms] OR ("nursing"[All Fields] AND "assistants"[All Fields]) OR "nursing assistants"[All Fields]	8,416
#20	Nursing aides	("nursing"[MeSH Terms] OR "nursing"[All Fields] OR "nursings"[All Fields]) AND "aides"[All Fields]	1,843
#21	Formal caregivers	("formal"[All Fields] OR "formalized"[All Fields]) AND ("caregiver s"[All Fields] OR "caregivers"[MeSH Terms] OR "caregivers"[All Fields] OR "caregiver"[All Fields] OR "caregiving"[All Fields])	2,921
#22	Combination:	<b>#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21</b>	526,064

PubMed	Search block: Frailty (I)		19. Jan 2022
Search #	Query	Search string	Results
#23	Frail	"frail"[All Fields] OR "frails"[All Fields] OR "frailty"[MeSH Terms] OR "frailty"[All Fields] OR "frailness"[All Fields]	34,147

PubMed	Search block: Long-term care (C)		19. Jan 2022
Search #	Query	Search string	Results
#24	Long-term care	"long term care"[MeSH Terms] OR ("long term"[All Fields] AND "care"[All Fields]) OR "long term care"[All Fields] OR ("long"[All Fields] AND "term"[All Fields] AND "care"[All Fields]) OR "long term care"[All Fields]	158,645
#25	Primary care	"primary health care"[MeSH Terms] OR ("primary"[All Fields] AND "health"[All Fields] AND "care"[All Fields]) OR "primary health care"[All Fields] OR ("primary"[All Fields] AND "care"[All Fields]) OR "primary care"[All Fields]	519,348
#26	Community healthcare	"community health services"[MeSH Terms] OR ("community"[All Fields] AND "health"[All Fields] AND "services"[All Fields]) OR "community health services"[All Fields] OR ("community"[All Fields] AND "healthcare"[All Fields]) OR "community healthcare"[All Fields]	453,397
#27	Community dwelling	"independent living"[MeSH Terms] OR ("independent"[All Fields] AND "living"[All Fields]) OR "independent living"[All Fields] OR ("community"[All Fields] AND "dwelling"[All Fields]) OR "community dwelling"[All Fields]	55,793
#28	Community nursing	("community"[All Fields] AND "nursing"[All Fields]) OR "community nursing"[All Fields]	85,995
#29	Home healthcare	("home environment"[MeSH Terms] OR ("home"[All Fields] AND "environment"[All Fields]) OR "home environment"[All Fields] OR "home"[All Fields] AND ("delivery of health care"[MeSH Terms] OR ("delivery"[All Fields] AND "health"[All Fields] AND "care"[All Fields]) OR "delivery of health care"[All Fields] OR "healthcare"[All Fields] OR "healthcare s"[All Fields] OR "healthcares"[All Fields])	68,971
#30	Home nursing	"home nursing"[MeSH Terms] OR ("home"[All Fields] AND "nursing"[All Fields]) OR "home nursing"[All Fields]	72,058

#31	Nursing home	"nursing homes"[MeSH Terms] OR ("nursing"[All Fields] AND "homes"[All Fields]) OR "nursing homes"[All Fields] OR ("nursing"[All Fields] AND "home"[All Fields]) OR "nursing home"[All Fields]	99,292
#32	Combination:	<b>#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR 30 OR #31</b>	1,155,165

PubMed	Combination of blocks		19. Jan 2022
Search #	Query	Search string	Results
#33	Combination (P):	<b>#4 OR #14 OR #22</b>	8,752,419
#34	Combination (PIC):	<b>#23 AND #32 AND #33</b>	11,877

For peer review only

# BMJ Open

## Nursing, Frailty, Functional Decline and Models of Care in Relation to Older People Receiving Long-term Care: A Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061303.R1
Article Type:	Protocol
Date Submitted by the Author:	30-Jun-2022
Complete List of Authors:	Flyum, Ida; Karlstad University Faculty of Health Science and Technology, Institute of Health Sciences, Department of Nursing; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing Gjevjon, Edith; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing Josse-Eklund, Anna; Karlstad University Faculty of Health Science and Technology, Institute of Health Sciences, Department of Nursing Lærum-Onsager, Ellisiv; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing Borglin, Gunilla; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing
<b>Primary Subject Heading</b>:	Nursing
Secondary Subject Heading:	Health services research, Geriatric medicine
Keywords:	GERIATRIC MEDICINE, PRIMARY CARE, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

# Nursing, Frailty, Functional Decline and Models of Care in Relation to Older People Receiving Long-term Care: A Scoping Review Protocol

*Ida Røed Flyum<sup>1,2</sup> RN, MNsc, PhD-candidate, Edith Roth Gjevjon<sup>1</sup> RN, MNsc, PhD, Anna Josse-Eklund<sup>2</sup> RN, DN, PhD, Ellisiv Lærum-Onsager<sup>1</sup> RN, MSc, PhD, Gunilla Borglin<sup>1</sup> RN, MSc, PhD, Professor in Nursing*

<sup>1</sup>Lovisenberg Diaconal University College, Department of Bachelor's in Nursing.  
Lovisenberggata 15B, NO-0456 Oslo, Norway

<sup>2</sup>Karlstad University, Faculty of Health, Nature and Technical Science, Institute of Health Sciences, Department of Nursing, Universitetsgatan 2, 651 88 Karlstad, Sweden

ORCID:

Ida Røed Flyum: <https://orcid.org/0000-0002-6256-4245>

Edith Roth Gjevjon: <https://orcid.org/0000-0002-9656-522X>

Anna Josse-Eklund: <https://orcid.org/0000-0002-1192-9697>

Ellisiv Lærum-Onsager: <https://orcid.org/0000-0001-9097-6100>

Gunilla Borglin: <https://orcid.org/0000-0002-7934-6949>

**Corresponding author:**

Ida Røed Flyum,  
Lovisenberggata 15B,  
NO-0456 Oslo, Norway  
[Ida.r.flyum@ldh.no](mailto:Ida.r.flyum@ldh.no)

Word count: 3401

## ABSTRACT

**Introduction:** Older people receiving healthcare in long-term care contexts (e.g., home healthcare, sheltered housing and nursing home contexts) are especially vulnerable to developing frailty and functional decline. Considering the negative effects associated with these conditions and the possibility of preventing them from progressing, it is vital that nurses possess a broad knowledge base related to them. Particularly as prevention related to these conditions lies well within their remit. Such knowledge could guide the development of effective models of care, ensuring continuity and, hence, quality of care. Our objective will be to review published literature on existing models of care targeting frailty and/or functional decline and how these conditions are described by older people themselves, significant others, and nurses in relation to long-term care.

**Methods and analysis:** The scoping review will be conducted in accordance with Arksey and O'Malley's methodological framework. Recent methodological developments will be considered. PubMed, CINAHL and PsycINFO will be searched. Eligibility criteria will be peer-reviewed papers and written in English. All types of study designs will be eligible and included papers will be quality- and ethically assessed. The PRISMA-P checklist for protocols and the PRISMA-ScR checklist were followed in this paper.

**Ethics and dissemination:** The findings will be published in an open-access, peer-reviewed journal. Additionally, the findings will guide a research project following the Medical Research Council's framework for developing and evaluating complex interventions. Thus, supporting us in developing a model of care related to the detection and prevention of frailty and/or functional decline among older people in a long-term care context.

**Registration details:** Open Science Framework, [10.17605/OSF.IO/FNHSA](https://doi.org/10.17605/OSF.IO/FNHSA).

**Strengths and limitations of this study:**

- Designing and reporting the protocol and upcoming scoping review in accordance with the PRISMA checklists will ensure the transparency, reliability and rigour of the review.
- The support of an information specialist in developing a comprehensive search strategy will ensure a higher probability of identifying eligible papers.
- Using a review team of five individuals will ensure independent assessment by two reviewers in all stages, as well as the opportunity to consult with a third person if necessary.
- Adopting a joint strategy of quality assessment and comprehensive overview may contribute to both identifying the gaps in the literature, as well as increasing the uptake and relevance of the results for practice and policy makers.
- Not including stakeholders in the conception and designing of this review might be a limitation.

## INTRODUCTION

Considering the potential adverse health outcomes of frailty and functional decline,[1, 2] as well as the potential reversibility of these conditions,[3] there is an undeniable need for effective models of care for the early detection and prevention of frailty and functional decline among older people in long-term care contexts (e.g., home healthcare, sheltered housing and nursing home contexts).[4, 5] Preventing frailty and functional decline as a part of a healthy ageing strategy is a globally important aim and has been promoted by both the European Commission and World Health organisation (WHO).[6, 7] Despite their global attention, both conditions are repeatedly described as closely related, and the terms are often used interchangeably.[8, 9] The nature of their relationship has been debated, even though the consensus appears to be that frailty predicts functional decline and disability.[3, 10] Our upcoming scoping review will depart from the idea of such a relationship.

It is well known that we live longer and, hence, are at an increased risk of multimorbidity, polypharmacy and the presentation of complex symptoms.[11] This indicates that the number of older people with frailty and at risk of functional decline[8, 11, 12] also is likely to substantially increase. The prevalence of frailty tends to vary, which might be because of the use of numerous definitions and screening instruments but also because frailty tends to increase with age.[13] Among community-dwelling older people (60+), the prevalence of frailty has been estimated to be between 2.6% and 60%[14, 15] and for nursing home patients between 19% and 75.6%.[15, 16] Frailty has also been associated with increased healthcare-related costs.[17] The early detection and preventative healthcare measures targeting these two conditions in long-term care contexts seems vital both for the healthcare offered and the quality of care for older patients. Unfortunately, such measures are challenging for several reasons.

First, older people receiving healthcare services in long-term care contexts are a heterogeneous population; they range from being relatively independent and in need of low-intensity care to being dependent on a range of activities of daily living (ADL) and in need of high intensity care.[11] Furthermore, it is fair to assume that through, for example, informal caregivers, these individuals' deteriorations might be compensated for and delayed over a longer period of time, thereby masking their actual care needs. This complex composition within both the population and the individuals themselves – masking actual care needs – increases the risk of adverse health outcomes because of the difficulties to detect the conditions.

1  
2  
3 Second, there is a growing number of older people ageing in place—that is, staying in their own  
4 homes.[18] This trend is believed to contribute to appropriate care at a lower cost compared  
5 with institutionalised care.[19, 20] Furthermore, according to Boland, et al. [21] there is  
6 insufficient evidence related to health-related outcomes to recommend either institutionalised  
7 care or home healthcare. Emphasising the preference of the older person when considering  
8 moving the locations of care should be taken into account. Research implies that most older  
9 people value their independence and prefer to remain in a familiar environment where they feel  
10 like they belong.[18] Stressing the importance of detecting and preventing conditions such as  
11 frailty and/or functional decline early on in this population. This might result in positive  
12 implications when it comes to their possibility for healthy ageing[6, 22] and contribute to more  
13 older people having the choice of ageing in place.[18, 22, 23] However, it has been documented  
14 that long-term care services experience limitations related to the following: time with patients,  
15 number of healthcare staff with adequate competence, collaboration with other professions,  
16 guidelines and protocols for care, high rates of sick leave, part-time workers and nurse  
17 retention.[23-25] This might increase the risk of nursing staff (e.g., registered nurses, registered  
18 practical nurses, licensed practical nurses, and nursing assistants/aides)[26]—hereinafter  
19 referred to as nurses—being forced to ration care.[27] This may result in patient monitoring  
20 being less prioritised and a further rationing of care that might lead to the signs and symptoms  
21 related to frailty and/or functional decline going unobserved. This can risk both patient safety  
22 and satisfaction.[28]

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39 Third, a prerequisite for detecting and preventing frailty and/or functional decline is a clear  
40 definition and understanding of the concepts, both medically and clinically. A number of  
41 definitions have been proposed, yet no consensus exists.[9, 29] In the upcoming scoping review,  
42 frailty will be understood in accordance with Clegg et al.'s[30] description as '*a state of*  
43 *vulnerability to poor resolution of homeostasis after a stressor event and is a consequence of*  
44 *cumulative decline in many physiological systems during a lifetime*' (p. 1). A critical point in  
45 the degenerative processes is reached where the homeostatic mechanisms are no longer  
46 sufficient. This results in vulnerability, that is, a seemingly small incidence (new drug or a  
47 'minor' infection), having a disproportionate effect on the individual's health.[30] This then  
48 increases the risk of adverse health outcomes such as falls, hospitalisation, disability and  
49 death.[1, 2] Furthermore, the dependency in ADLs in people with frailty may fluctuate  
50 substantially. This is often referred to as 'unstable disability',[30] and we postulate that such  
51 fluctuating disability could be understood as functional decline.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 For the upcoming review, functional decline will be defined as a new loss of independence in  
6 self-care activities or as a deterioration in self-care skills, here as measured on an ADL scale  
7 (e.g., bathing, dressing, transferring from bed to chair, using the toilet, etc.) and/or on an  
8 instrumental activities of daily living (IADL) scale (e.g., shopping, housekeeping, preparing  
9 meals, etc.).[31, 32] Functional decline among older people can also result in compromises  
10 beyond ADL for example physical problems such as falls and malnutrition and psychosocial  
11 problems such as depression and delirium.[33] According to Hébert [34] functional decline may  
12 manifest subacutely or acutely. Subacute functional decline slowly develops over time and is  
13 more difficult to detect than acute functional decline, particularly if the patients are not screened  
14 for physical or mental capacity changes. Usually, this is caused by chronic disease or a new,  
15 undetected disease, but it may also arise because of polypharmacy, cognitive decline or a  
16 psychiatric condition. Acute functional decline often manifests in a couple of days to a week  
17 and requires emergent medical attention and hospitalisation. It can be caused by an acute  
18 incident (e.g., infection, fall or stroke), malfunction in compensatory mechanisms of a chronic  
19 condition or a psychological crisis (e.g., death of a significant other or hospital admission).

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32 Among healthcare professionals, nurses are the largest professional group. They are often the  
33 first point of contact, and they are also the group that spends the most time with the patients.  
34 Thus, the management of care, including detecting and preventing the signs and symptoms of  
35 frailty and/or functional decline, lies both within their remit and range of responsibilities.  
36 Despite this, we have not been able to identify any published reviews summarising the evidence  
37 within this field. Instead, recent reviews have focused on areas such as the effect of  
38 interventions[35-38] and screening tools.[39-41] Furthermore, we might argue that to develop  
39 effective models of care related to these conditions, it is critical to understand how frailty and  
40 functional decline might be described beyond our medical understanding and by important  
41 stakeholders.

42  
43  
44  
45  
46  
47  
48  
49  
50  
51 Additionally, nurses are expected to provide a diverse range of healthcare services, and one of  
52 their functions is to assess, diagnose, intervene and evaluate a patient's personal health  
53 needs.[42, 43] Consequently, nursing staff can play a major role in delivering a safe and  
54 evidence-based practice that involves detecting and establishing appropriate care actions for  
55 older people, regardless of their conditions. Working in accordance with structured and logical  
56 (effective) models of care to detect, prevent or postpone frailty and/or functional decline among  
57  
58  
59  
60

1  
2  
3 older people in long-term care is vital. Hence, our objective will be to review the literature on  
4 existing models of care, frameworks, patient care pathways and/or clinical practice guidelines  
5 targeting frailty and/or functional decline, as well as how these two conditions are described by  
6 key stakeholders (e.g., older people themselves, their significant others, and nurses) in relation  
7 to long-term care.  
8  
9  
10

## 11 12 13 **METHOD AND ANALYSIS** 14

15 The upcoming scoping review will be conducted in accordance with Arksey and O'Malley's  
16 [44] methodological frameworks for conducting scoping studies stage 1-5. Thus, leaving out  
17 the optional stage regarding consultation with stakeholders and experts. Additionally,  
18 methodological developments will be considered, that is, Levac, et al. [45] and Daudt, et al.  
19 [46] As the topic of interest for the upcoming study is broad and complex in nature, in addition  
20 to the lack of previously comprehensive reviews, a scoping review design is deemed  
21 appropriate.[44] This design allows for inclusion of a diverse range of study designs and papers  
22 of differing levels of quality. Furthermore, the iterative methodological process offers us the  
23 opportunity to revise our research questions (i.e., remove, amend, or add questions) as we gain  
24 more familiarity with the research area.[44] During the search processes the final inclusion and  
25 exclusion criteria will be decided upon. This might mean excluding certain conditions or  
26 specific forms of care (e.g., palliative care or stroke), change of population and specification of  
27 the context. This flexibility is important when reviewing a topic as broad, uncharted, and  
28 complex as ours. The iterative approach allows us to start out with broad research questions.  
29 This is favourable as we aim to summarise the research findings in our research area as well as  
30 to create an overview of both gaps in the literature and of areas which have been thoroughly  
31 researched.[44] The included papers will undergo ethical and critical appraisal,[45, 47, 48]  
32 relevant data will be extracted,[45, 49] and data answering the review questions will be  
33 analysed by content analysis.[50]  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 This protocol will utilise the Preferred Reporting Items for Systematic Reviews and Meta-  
51 Analyses Extension for Scoping Reviews (PRISMA-ScR) checklist,[51] as well as the  
52 PRISMA-P checklist for reporting protocols (Supplementary file 1-2),[52] which is  
53 recommended for scoping reviews and systematic reviews.[53] As recommended, the  
54 upcoming review is registered in the Open Science Framework (OSF) (registration number  
55 [10.17605/OSF.IO/FNHSA](https://doi.org/10.17605/OSF.IO/FNHSA). Registered and last updated on 30 June 2021).  
56  
57  
58  
59  
60

### Stage 1: Identifying the research question

In accordance with Arksey and O'Malley [44] tentative and broad research questions were formulated following the PICoS (Population, Phenomenon of Interest, Context and Study design) framework (Table 1). In accordance with the iterative approach of a scoping review, the tentative research questions may be reformulated as we gain familiarity with the research area.[44]

- What models of care, frameworks, patient care pathways and/or clinical practice guidelines targeting the detection and prevention of frailty and subsequently functional decline among older people are described in relation to long-term care?
- How is the condition of frailty described by key stakeholders in long-term care?
- How is the condition of functional decline described by key stakeholders in long-term care?

Furthermore, subquestions will encompass the following: By whom are the questions in the literature answered, in what specific contexts, in relation to whom or what? Which research designs have been utilised? How is the methodological quality appraised?

**Table 1.** PICoS framework for determination of eligibility of review questions

Criteria	Determinants
<b>Population</b>	Older people (65+ years) Significant others Nurses[26]
<b>Phenomenon of Interest</b>	Descriptions of models of care, frameworks, patient care pathways and/or clinical practice guidelines targeting the detection and prevention of frailty and/or functional decline among older people  Descriptions of frailty and/or functional decline among older people
<b>Context</b>	Long-term care, e.g., home healthcare, sheltered housing and nursing homes[4, 5]
<b>Study design</b>	All study designs

### Stage 2: Identifying relevant studies

Systematic searches will be conducted in PubMed, CINAHL and PsycINFO. These databases cover the majority of the published, peer-reviewed health service research. The search strategies will be constructed following the PICoS categories and will be tailored to each database. To

1  
2  
3 achieve a comprehensive search strategy with sensitivity and specificity, we will include both  
4 controlled subject headings such as MeSH,[54] as well as keywords and synonyms. No time  
5 limitation will be implemented because of the lack of earlier reviews and the aim to  
6 comprehensively map the area of interest.[44] A preliminary search strategy was constructed  
7 for PubMed in collaboration with an information specialist at Karlstad University  
8 (Supplementary File 3, last updated on 19 January 2022). Additionally, the reference lists of all  
9 the included papers will be searched.[44, 54, 55] To ensure transparency in the iterative process,  
10 the first author will keep a logbook throughout the entire project to track amendments from this  
11 protocol and other decisions made, including the rationale.[55, 56] Considering what types of  
12 research will most likely be relevant for answering our research questions, as well as the time  
13 and resources needed searching for grey literature,[55] we have decided to include only  
14 published, peer-reviewed research.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Stage 3: Study selection**

26 To ensure consistency, reliability and validity in the selection process, eligibility criteria will  
27 be constructed.[45] A tentative summary of the eligibility criteria is described below. Still, in  
28 accordance with the iterative process, the eligibility criteria might be refined as familiarity  
29 with the field increases and can then be applied to all citations post hoc.[44]  
30  
31  
32  
33  
34  
35

36 Using the eligibility criteria, two independent reviewers will assess the relevance of all titles  
37 and abstracts in the search results. The full text of the relevant papers, as well as those where  
38 relevance is unclear, will be assessed for inclusion[44] by two reviewers.[45, 46] Meetings will  
39 be held regularly to address any uncertainties.[45] Disagreements will be resolved through  
40 discussion and, if necessary, consultation with a third reviewer. The selection process will be  
41 documented using the PRISMA flowchart[57] (Figure 1). The data programme Rayyan will be  
42 utilised using the option 'blind on' to ensure an independent review.[58]  
43  
44  
45  
46  
47  
48  
49

50 **Insert --- Figure 1. about here ---**

51  
52 The eligibility criteria relate to the categories in PICoS, as well as the research type, language  
53 and ethical considerations. The population will be limited to older people, their significant  
54 others, and nurses. Older people will be defined as all people over the age of 65 years,  
55 considering that this is a standard cut-off for older people in most research and databases today.  
56 Significant others are tentatively defined as individuals with a close relationship to the older  
57  
58  
59  
60

person, not defined by kinship or by being an unpaid carer. As previously stated, nurses will be defined as nursing staff (e.g., registered nurses, registered practical nurses, licensed practical nurses, and nursing assistants/aides).[26] Because there exists no consensus definition of frailty or functional decline, we will use the definitions presented in the introduction of this protocol as the inclusion criteria. The context will be defined as long-term care contexts, for example, home healthcare, sheltered housing and nursing homes.[4, 5] All study designs will be included. Because the aim of the review is to summarise evidence from published, peer-reviewed research, we will exclude research types not complying with these parameters, such as letters to the editor and discussion papers. Considering time and resources, we will only include papers that do not need translation, that is, those in English. There is a rising appreciation of the contribution that ethical quality assessment in reviews may have on sustainable and ethical research.[47, 48] To contribute to this work, we have constructed a tentative list of the ethical requirements for the included papers, as influenced by Weingarten, et al. [47] (Table 2). Depending on the total number of eligible papers and the overall methodological and ethical quality, a decision regarding excluding papers of subpar standards will be made.

**Table 2.** Ethical requirements

Was the study approved by an ethical research committee?	Yes/No
Was informed consent retrieved from all participants?	Yes/No
Were the personal data/transcriptions/recordings properly managed, stored and disposed off?	Yes/No
Was the relevance of the study clearly justified?	Yes/No
Was any conflict of interests or funding declared?	Yes/No

#### **Stage 4: Charting the data**

A data charting form will be iteratively developed to facilitate the systematic charting of data. Tentative data charting items are shown in Box 1, which will be iteratively developed throughout the review process. Two reviewers will develop and independently test the form on the first five to ten relevant papers.[45, 49] Thereafter, two independent reviewers will apply the form to all included papers. Disagreements will be resolved by discussion with a third review team member.

#### **Box. 1** Tentative data charting items

**Full reference** (including authors, year of publication, journal, etc.)

**Title**

**Aim, objective and/or research question**

**Population and participant characteristics** (e.g., total number of participants and number per subgroup, i.e., older people, significant others, and nurses. Age range for the older people and type of significant other, as for example spouse, child, or neighbour. As well as type of nurse, such as registered nurse or nursing assistant)

**Phenomenon of Interest** (e.g., frailty, functional decline, both conditions, models of care, practice guidelines)

**Study context and country**

**Sampling method**

**Study design** (e.g., type of qualitative, quantitative, or mixed/multiple methods)

**Data collection method** (e.g., individual interviews, focus groups or survey)

**Data analysis** (e.g., type of thematic analysis, content analysis, descriptive numerical analysis)

**Relevant findings** (e.g., themes, categories, numerical data, and outcomes, types of models of care, possible theoretical underpinnings)

**Quality assessment** (the Critical Appraisal Skills Programme checklists[59] or the mixed methods appraisal tool[60])

**Ethical assessment** (see Table 2[47] [48])

Quality appraisal in scoping reviews is a topic of debate, with researchers both for[45, 46, 61] and against it.[44, 49] Despite this all the included papers will be quality assessed but included regardless of the results. No weighting of the evidence will be done;[44] rather, a quality assessment will be utilised to identify potential gaps in the literature related to high-quality research.[45] The quality assessment will be conducted by two independent reviewers using the checklists from the Critical Appraisal Skills Programme (CASP).[59] For mixed method studies, the mixed method appraisal tool will be applied.[60]

### **Stage 5: Collating, summarising and reporting the results**

The charted data including the relevant findings from each included paper will be presented in both a schematical overview and as a narrative account. Numerical analysis of the quantitative data will be descriptive and focus on the nature, extent and distribution of the data. How the results are presented will depend on the findings (e.g., tables, chart, figures).[49] The qualitative data will most likely be analysed using qualitative content analysis,[50] as recommended by

1  
2  
3 Levac, et al. [45] Still, considering the iterative methodologically approach we might decide to  
4 change the method for qualitative analysis as we gain familiarity with the evidence. Irrespective  
5 of which method of analysis is chosen the focus will be on the manifest content. Using a  
6 descriptive approach and focusing on manifest content entails a very low degree of  
7 interpretation.[62] This is in accordance with the aim of summarising—not synthesising—  
8 evidence in a scoping review.[44] Additionally, the PAGER (Patterns, Advances, Gaps,  
9 Evidence for practice and Research recommendations) reporting guidelines framework for  
10 scoping reviews will be used to secure the quality of our reporting.[63] Two reviewers will be  
11 responsible for this stage, and regular meetings will be conducted with the whole review team  
12 where decisions related to analysis and presentation of findings will be discussed and decided  
13 upon.  
14  
15  
16  
17  
18  
19  
20  
21  
22

### 23 **Patient and public involvement**

24 No patients were involved in the conception or design of the upcoming review.  
25  
26  
27  
28

### 29 **ETHICS AND DISSEMINATION**

30  
31  
32 Despite reviews being excluded from ethical assessment by ethical review authorities,[64-66]  
33 the need for ethical considerations when conducting reviews has been highlighted by  
34 Vergnes, et al. [48] and Weingarten, et al. [47] Vergnes, et al. [48] offers the following  
35 arguments pro ethical assessment, i) raising awareness of the importance of upholding the  
36 high ethical standard in research with humans, ii) not basing practice on trials not following  
37 ethical principles, iii) respecting the conflict of interest statement as well as the financial  
38 disclosure, iv) discouraging publication of non-ethical research under the cover of “systematic  
39 review”, v) respecting confidentiality and informed consent. Additionally, as there is no  
40 consensus on how to assess ethical issues in reviews Weingarten, et al. [47] have proposed the  
41 use of standardised protocols for assessing ethical aspects (e.g., Table 2). We will contribute  
42 to this by considering the ethical standards of all eligible papers.  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 Furthermore, to ensure an effective literature review, as well as avoid research waste,[67] we  
53 have conducted a thorough exploratory search to assess the need for the upcoming review. The  
54 ethical importance of writing this protocol should also be mentioned because protocols  
55 alongside the precise logging of amendments in the final review manuscript are an important  
56 part of making our review transparent to criticism.  
57  
58  
59  
60

The scoping review will be published in a peer-reviewed, open-access journal. Tentatively, the findings will be reported by winter 2022. Additionally, the findings will be utilised in a research project following the Medical Research Council's framework for developing and evaluating complex interventions[68] to inform the development of a model of care related to the detection and prevention of frailty and/or functional decline among older people in a long-term care context.

### **ACKNOWLEDGEMENTS**

We would like to thank XXX, Information Specialist at Karlstad University, for her contribution to the search strategies presented in this protocol.

### **AUTHORS' CONTRIBUTIONS**

IRF, GB, ERG, AJ-E and EL-O were responsible for the study's inception and design. IRF was responsible for drafting the first version of the manuscript. GB, ERG, AJ-E and EL-O were responsible for the critical revision of the paper and for adding important intellectual content. GB supervised the study. All authors read and approved the final manuscript.

### **FUNDING STATEMENT**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

### **COMPETING INTERESTS STATEMENT**

The authors of this scoping review protocol declare no competing interests in connection with this manuscript.

### **LICENCE STATEMENT**

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the

Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

**Figure 1.** PRISMA-flowchart: Overview of the study selection process

## REFERENCES

1. Fried LP, Tangen CM, Walston J, et al. Frailty in Older Adults: Evidence for a Phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56(3):M146-M57. doi: 10.1093/gerona/56.3.M146
2. Vermeiren S, Vella-Azzopardi R, Beckwée D, et al. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. *J Am Med Dir Assoc* 2016;17(12):1163.e1-63.e17. doi: 10.1016/j.jamda.2016.09.010
3. Sezgin D, Liew A, O'Donovan MR, et al. Pre-frailty as a multi-dimensional construct: A systematic review of definitions in the scientific literature. *Geriatr Nurs* 2020;41(2):139-46. doi: 10.1016/j.gerinurse.2019.08.004
4. National Institute on Ageing. Enabling the Future Provision of Long-Term Care in Canada. Toronto, 2019.
5. National Institute on Aging. What is Long-Term Care? 2017 [Available from: <https://www.nia.nih.gov/health/what-long-term-care>].
6. World health organization. Decade of Healthy Ageing 2020-2030, 2020.
7. Cano A, Dargent G, Carriazo A, et al. Tackling frailty and functional decline: Background of the action group A3 of the European innovation partnership for active and healthy ageing. *Maturitas* 2018;115:69-73. doi: 10.1016/j.maturitas.2018.06.009
8. Beaton K, McEvoy C, Grimmer K. Identifying indicators of early functional decline in community-dwelling older people: A review. *Geriatr Gerontol Int* 2014;15(2):133-40. doi: 10.1111/ggi.12379
9. Sezgin D, O'Donovan M, Cornally N, et al. Defining frailty for healthcare practice and research: A qualitative systematic review with thematic analysis. *Int J Nurs Stud* 2019;92:16-26. doi: 10.1016/j.ijnurstu.2018.12.014
10. Church S, Rogers E, Rockwood K, et al. A scoping review of the Clinical Frailty Scale. *BMC Geriatr* 2020;20:1-18. doi: 10.1186/s12877-020-01801-7
11. Roller-Wirnsberger R, Singler K, Polidori MC. Learning Geriatric Medicine: A Study Guide for Medical Students: Springer International Publishing AG 2018.
12. Fried LP, Ferrucci L, Darer J, et al. Untangling the Concepts of Disability, Frailty, and Comorbidity: Implications for Improved Targeting and Care. *J Gerontol A Biol Sci Med Sci* 2004;59(3):M255-M63. doi: 10.1093/gerona/59.3.M255
13. Kehler DS, Ferguson T, Stammers AN, et al. Prevalence of frailty in Canadians 18–79 years old in the Canadian Health Measures Survey. *BMC Geriatr* 2017;17 doi: 10.1186/s12877-017-0423-6
14. Collard RM, Boter H, Schoevers RA, et al. Prevalence of Frailty in Community-Dwelling Older Persons: A Systematic Review. *J Am Geriatr Soc* 2012;60(8):1487-92. doi: 10.1111/j.1532-5415.2012.04054.x
15. O'Caioimh R, Galluzzo L, Rodríguez-Laso Á, et al. Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis. *Ann Ist Super Sanità* 2018;54(3):226-38. doi: 10.4415/ANN\_18\_03\_10

16. Kojima G. Prevalence of Frailty in Nursing Homes: A Systematic Review and Meta-Analysis. *J Am Med Dir Assoc* 2015;16(11):940-45. doi: 10.1016/j.jamda.2015.06.025
17. Kojima G. Increased healthcare costs associated with frailty among community-dwelling older people: A systematic review and meta-analysis. *Arch Gerontol Geriatr* 2019;84 doi: 10.1016/j.archger.2019.06.003
18. Pani-Harreman KE, Bours GJJW, Zander I, et al. Definitions, key themes and aspects of 'ageing in place': a scoping review. *Ageing Soc* 2021;41:2026-59. doi: 10.1017/S0144686X20000094
19. Genet N, Boerma W, Kroneman M, et al. Home care across Europe: Current structure and future challenges. *European Observatory on Health Systems and Policies* 2012
20. Horner B, Boldy DP. The benefit and burden of "ageing-in-place" in an aged care community. *Aust Health Rev* 2008;32(2):356-65. doi: 10.1071/ah080356
21. Boland L, Légaré F, Perez MMB, et al. Impact of home care versus alternative locations of care on elder health outcomes: an overview of systematic reviews. *BMC Geriatr* 2017;17:1-15. doi: 10.1186/s12877-016-0395-y
22. Norwegian Ministry of Health and Care Services. A full life - all your life: A Quality Reform for Older Persons. 2019
23. Spasova S, Baeten R, Coster S, et al. Challenges in long-term care in Europe - A study of national policies 2018. Brussels: European Commission: European Social Policy Network (ESPN), 2018.
24. Valizadeh L, Zamanzadeh V, Saber S, et al. Challenges and Barriers Faced by Home Care Centers: An Integrative Review. *Medical - Surgical Nursing Journal* 2018;7(3):e83486. doi: 10.5812/msnj.83486
25. Organisation for Economic Co-operation and Development (OECD). Health at a Glance 2021: OECD Indicators 2021.
26. Chu CH, McGilton KS, Spilsbury K, et al. Strengthening International Research in Long-Term Care: Recommended Common Data Elements to Support Clinical Staff Training. *Gerontol Geriatr Med* 2021;7:1-17. doi: 10.1177/2333721421999312
27. Kalánková D, Žiaková K, Kurucová R. Approaches to understanding the phenomenon of missed/rationed/unfinished care - a literature review. *Central European Journal of Nursing and Midwifery* 2019;10(1):1005-16. doi: 10.15452/CEJNM.2019.10.0007
28. Kalánková D, Kirwan M, Bartoníčková D, et al. Missed, rationed or unfinished nursing care: A scoping review of patient outcomes. *J Nurs Manag* 2020;28(8):1783-97. doi: 10.1111/jonm.12978
29. Junius-Walker U, Onder G, Soleymani D, et al. The essence of frailty: A systematic review and qualitative synthesis on frailty concepts and definitions. *Eur J Intern Med* 2018;56:3-10. doi: 10.1016/j.ejim.2018.04.023
30. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *Lancet* 2013;381(9868):752-62. doi: 10.1016/S0140-6736(12)62167-9
31. Fortinsky RH, Covinsky KE, Palmer RM, et al. Effects of functional status changes before and during hospitalization on nursing home admission of older adults. *J Gerontol A Biol Sci Med Sci* 1999;54(10):M521-6. doi: 10.1093/gerona/54.10.m521
32. Hébert R, Brayne C, Spiegelhalter D. Factors Associated with Functional Decline and Improvement in a Very Elderly Community-dwelling Population. *Am J Epidemiol* 1999;150(5):501-10. doi: 10.1093/oxfordjournals.aje.a010039
33. de Vos AJBM, Asmus-Szepesi KJE, Bakker TJEM, et al. Integrated approach to prevent functional decline in hospitalized elderly: the Prevention and Reactivation Care Program (PReCaP). *BMC Geriatr* 2012;12 doi: 10.1186/1471-2318-12-7
34. Hébert R. Functional decline in old age. *CMAJ* 1997;157(8):1037-45.

35. Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: a systematic review. *JBI Database System Rev Implement Rep* 2018;16(1):140-232. doi: 10.11124/JBISRIR-2017-003382
36. Travers J, Romero-Ortuno R, Bailey J, et al. Delaying and reversing frailty: a systematic review of primary care interventions. *Br J Gen Pract* 2019;69(678):e61-e69. doi: 10.3399/bjgp18X700241
37. Verstraten CCJMM, Metzethin SF, Schoonhoven L, et al. Optimizing patients' functional status during daily nursing care interventions: A systematic review. *Res Nurs Health* 2020;43(5):478-88. doi: 10.1002/nur.22063
38. Mareschal J, Genton L, Collet T-H, et al. Nutritional Intervention to Prevent the Functional Decline in Community-Dwelling Older Adults: A Systematic Review. *Nutrients* 2020;12(9):1-21. doi: 10.3390/nu12092820
39. Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Predicting risk and outcomes for frail older adults: an umbrella review of frailty screening tools. *JBI Database System Rev Implement Rep* 2017;15(4):1154-208. doi: 10.11124/jbisrir-2016-003018
40. Faller JW, Pereira DdN, de Souza S, et al. Instruments for the detection of frailty syndrome in older adults: A systematic review. *PLoS One* 2019;14(4):e0216166. doi: 10.1371/journal.pone.0216166
41. Roedl KJ, Wilson LS, Fine J. A systematic review and comparison of functional assessments of community-dwelling elderly patients. *J Am Assoc Nurse Pract* 2016;28(3):160-9. doi: 10.1002/2327-6924.12273
42. Henderson V. *The Nature of Nursing a Definition and its Implications for Practice, Research, and Education*: Macmillan 1966.
43. Richards DA, Borglin G. 'Shitty nursing' – The new normal? *Int J Nurs Stud* 2019;91:148-52. doi: 10.1016/j.ijnurstu.2018.12.018
44. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;8(1):19-32. doi: 10.1080/1364557032000119616
45. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement Sci* 2010;5:69. doi: 10.1186/1748-5908-5-69
46. Daudt HML, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team's experience with Arksey and O'Malley's framework. *BMC Med Res Methodol* 2013;13:48. doi: 10.1186/1471-2288-13-48
47. Weingarten MA, Paul M, Leibovici L. Assessing ethics of trials in systematic reviews. *BMJ* 2004;328:1013-14. doi: 10.1136/bmj.328.7446.1013
48. Vergnes J-N, Marchal-Sixou C, Nabet C, et al. Ethics in systematic reviews. *J Med Ethics* 2010;36(12):771-74. doi: 10.1136/jme.2010.039941
49. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth* 2020;18(10):2119-26. doi: 10.11124/JBIES-20-00167
50. Elo S, Kyngäs H. The qualitative content analysis process. *J Adv Nurs* 2008;62(1):107-15. doi: 10.1111/j.1365-2648.2007.04569.x
51. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR) : Checklist and Explanation. *Ann Intern Med* 2018;169:467-73. doi: 10.7326/M18-0850
52. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647. doi: 10.1136/bmj.g7647

53. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1
54. Bramer WM, de Jonge GB, Rethlefsen ML, et al. A systematic approach to searching: an efficient and complete method to develop literature searches. *J Med Libr Assoc* 2018;106(4):531-41. doi: 10.5195/jmla.2018.283
55. Booth A. Searching for qualitative research for inclusion in systematic reviews: a structured methodological review. *Syst Rev* 2016;5:74. doi: 10.1186/s13643-016-0249-x
56. Pollock D, Davies EL, Peters MDJ, et al. Undertaking a scoping review: A practical guide for nursing and midwifery students, clinicians, researchers, and academics. *J Adv Nurs* 2021;77(4):2102-13. doi: 10.1111/jan.14743
57. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71
58. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. *Syst Rev* 2016;5:210. doi: 10.1186/s13643-016-0384-4
59. Critical Appraisal Skills Programme. CASP Checklists n.d. [Available from: <https://casp-uk.net/casp-tools-checklists/>]
60. Hong QN, Pluye P, Fàbregues S, et al. Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study. *J Clin Epidemiol* 2019;111:49-59. doi: 10.1016/j.jclinepi.2019.03.008
61. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. *Health Info Libr J* 2009;26(2):91-108. doi: 10.1111/j.1471-1842.2009.00848.x
62. Lindgren B-M, Lundman B, Graneheim UH. Abstraction and interpretation during the qualitative content analysis process. *Int J Nurs Stud* 2020;108:103632-32. doi: 10.1016/j.ijnurstu.2020.103632
63. Bradbury-Jones C, Aveyard H, Herber OR, et al. Scoping reviews: the PAGER framework for improving the quality of reporting. *Int J Soc Res Methodol* 2021:1-14. doi: 10.1080/13645579.2021.1899596
64. The Ministry of Education and Cultural Affairs. The Act concerning the Ethical Review of Research Involving Humans (SFS number: 2003:460), 2003.
65. the Health Research Act. Act on medical and health research, 2008.
66. Norwegian centre for research data. n.d. [Available from: <https://www.nsd.no>]
67. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *Lancet* 2009;374(9683):86-89. doi: 10.1016/S0140-6736(09)60329-9
68. Skivington K, Matthews L, Simpson SA, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. *BMJ* 2021;374:n2061 doi: 10.1136/bmj.n2061


#### REFERENCES CITED IN TABLE 1 AND 2:

4. National Institute on Ageing. Enabling the Future Provision of Long-Term Care in Canada. Toronto, 2019.
5. National Institute on Aging. What is Long-Term Care? 2017 [Available from: <https://www.nia.nih.gov/health/what-long-term-care>].
26. Chu CH, McGilton KS, Spilsbury K, et al. Strengthening International Research in Long-Term Care: Recommended Common Data Elements to Support Clinical Staff Training. *Gerontol Geriatr Med* 2021;7:1-17. doi: 10.1177/2333721421999312
47. Weingarten MA, Paul M, Leibovici L. Assessing ethics of trials in systematic reviews. *BMJ* 2004;328:1013-14. doi: 10.1136/bmj.328.7446.1013

- 1  
2  
3 48. Vergnes J-N, Marchal-Sixou C, Nabet C, et al. Ethics in systematic reviews. *J Med Ethics*  
4 2010;36(12):771-74. doi: 10.1136/jme.2010.039941  
5 59. Critical Appraisal Skills Programme. CASP Checklists n.d. [Available from: [https://casp-](https://casp-uk.net/casp-tools-checklists/)  
6 [uk.net/casp-tools-checklists/](https://casp-uk.net/casp-tools-checklists/)  
7 60. Hong QN, Pluye P, Fàbregues S, et al. Improving the content validity of the mixed  
8 methods appraisal tool: a modified e-Delphi study. *J Clin Epidemiol* 2019;111:49-59.  
9 doi: 10.1016/j.jclinepi.2019.03.008  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Figure 1. PRISMA-flowchart: Overview of the study selection process



## SUPPLEMENTARY FILE 1

**Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist**

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
<b>TITLE</b>			
Title	1	Identify the report as a scoping review.	Title page
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	1
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	3-6
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	5-6
<b>METHODS</b>			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	6

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	8
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Supplementary File 3
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	Box 1

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	9
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	10
<b>RESULTS</b>			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Not applicable for the protocol
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Not applicable for the protocol
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not applicable for the protocol
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Not applicable for the protocol
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Not applicable for the protocol
<b>DISCUSSION</b>			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of	Not applicable for the protocol

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
		evidence available), link to the review questions and objectives, and consider the relevance to key groups.	
Limitations	20	Discuss the limitations of the scoping review process.	Not applicable for the protocol
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	Not applicable for the protocol
<b>FUNDING</b>			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	11

JB I = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

\* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## SUPPLEMENTARY FILE 2

### PRISMA-P 2015 Checklist

This checklist was retrieved by the authors of this protocol from the PRISMA web page, and is an adapted version of Table 3 in Moher, et al.<sup>52</sup>: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
<b>ADMINISTRATIVE INFORMATION</b>					
<b>Title</b>					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Title page
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Registration</b>	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1 and 6
<b>Authors</b>					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Title page
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11
<b>Amendments</b>	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7
<b>Support</b>					
Sources	5a	Indicate sources of financial or other support for the review	<input type="checkbox"/>	<input checked="" type="checkbox"/>	11

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
					No funders/sponsors
Sponsor	5b	Provide name for the review funder and/or sponsor	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Not applicable
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Not applicable
<b>INTRODUCTION</b>					
<b>Rationale</b>	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	3-6
<b>Objectives</b>	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	6
<b>METHODS</b>					
<b>Eligibility criteria</b>	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
<b>Information sources</b>	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7
<b>Search strategy</b>	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Supplementary File 3
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
<b>Data items</b>	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Box 1
<b>Outcomes and prioritization</b>	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Box 1
<b>Risk of bias in individual studies</b>	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
<b>DATA</b>					
<b>Synthesis</b>	15a	Describe criteria under which study data will be quantitatively synthesized	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
<b>Meta-bias(es)</b>	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Confidence in cumulative evidence</b>	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

1 by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
 26/bmjopen-2022-061303 on 23 August 2022. Downloaded from <http://bmjopen.bmj.com/> on May 15, 2025 at Department GEZ-LTA  
 ErasmusHogeschool

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## SUPPLEMENTARY FILE 3

Tentative search strategy: PubMed

Last updated on: 19.01.22

**Question 2:** How is the concept of frailty described and understood by older people, their significant others, and nurses in long-term care contexts?

PubMed	Search block: Older people (P)		19. Jan 2022
Search #	Query	Search string	Results
#1	Aged	"aged"[MeSH Terms] OR "aged"[All Fields]	5,765,926
#2	Elderly	"aged"[MeSH Terms] OR "aged"[All Fields] OR "elderly"[All Fields] OR "elderlies"[All Fields] OR "elderly s"[All Fields] OR "elderlys"[All Fields]	5,823,455
#3	Older	"older"[All Fields] OR "olders"[All Fields]	496,898
#4	Combination:	<b>#1 OR #2 OR #3</b>	5,978,243

PubMed	Search block: Significant others (P)		19. Jan 2022
Search #	Query	Search string	Results
#5	Significant others	"significant"[All Fields] AND "other*"[All Fields]	763,016
#6	Informal caregivers	"caregivers"[MeSH Terms] OR "caregiver*"[All Fields] OR ("informal"[All Fields] AND "caregiver*"[All Fields])	92,958
#7	Family	"family"[MeSH Terms] OR "family"[All Fields] OR "families"[All Fields] OR "family s"[All Fields] OR "familys"[All Fields]	1,542,673
#8	Relatives	"relative"[All Fields] OR "relatives"[All Fields] OR "relative s"[All Fields]	984,365
#9	Family caregivers	"caregivers"[MeSH Terms] OR "caregiver*"[All Fields] OR ("family"[All Fields] AND "caregiver*"[All Fields])	92,958
#10	Spouses	"spouse s"[All Fields] OR "spouses"[MeSH Terms] OR "spouses"[All Fields] OR "spouse"[All Fields]	34,339
#11	Husbands	"husband s"[All Fields] OR "husband"[All Fields] OR "husbands"[All Fields]	14,379
#12	Wives	"wife"[All Fields] OR "wives"[All Fields] OR "wife s"[All Fields]	11,491
#13	Next-of-kin	"Next-of-kin"[All Fields]	1,920
#14	Combination:	<b>#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13</b>	3,174,444

PubMed	Search block: Nursing staff (P)		19. Jan 2022
Search #	Query	Search string	Results
#15	Nurse	"nurse s"[All Fields] OR "nurses"[MeSH Terms] OR "nurses"[All Fields] OR "nurse"[All Fields] OR "nurses s"[All Fields]	408,405

#16	Nursing personnel	"nursing staff"[MeSH Terms] OR ("nursing"[All Fields] AND "staff"[All Fields]) OR "nursing staff"[All Fields] OR ("nursing"[All Fields] AND "personnel"[All Fields]) OR "nursing personnel"[All Fields] OR "nurses"[MeSH Terms] OR "nurses"[All Fields] OR ("nursing"[All Fields] AND "personnel"[All Fields])	365,108
#17	Healthcare assistants	"allied health personnel"[MeSH Terms] OR ("allied"[All Fields] AND "health"[All Fields] AND "personnel"[All Fields]) OR "allied health personnel"[All Fields] OR ("healthcare"[All Fields] AND "assistants"[All Fields]) OR "healthcare assistants"[All Fields]	56,879
#18	Healthcare aides	("delivery of health care"[MeSH Terms] OR ("delivery"[All Fields] AND "health"[All Fields] AND "care"[All Fields]) OR "delivery of health care"[All Fields] OR "healthcare"[All Fields] OR "healthcare s"[All Fields] OR "healthcares"[All Fields]) AND "aides"[All Fields]	1,248
#19	Nursing assistants	"nursing assistants"[MeSH Terms] OR ("nursing"[All Fields] AND "assistants"[All Fields]) OR "nursing assistants"[All Fields]	8,416
#20	Nursing aides	("nursing"[MeSH Terms] OR "nursing"[All Fields] OR "nursings"[All Fields]) AND "aides"[All Fields]	1,843
#21	Formal caregivers	("formal"[All Fields] OR "formalized"[All Fields]) AND ("caregiver s"[All Fields] OR "caregivers"[MeSH Terms] OR "caregivers"[All Fields] OR "caregiver"[All Fields] OR "caregiving"[All Fields])	2,921
#22	Combination:	<b>#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21</b>	526,064

PubMed	Search block: Frailty (I)		19. Jan 2022
Search #	Query	Search string	Results
#23	Frail	"frail"[All Fields] OR "frails"[All Fields] OR "frailty"[MeSH Terms] OR "frailty"[All Fields] OR "frailness"[All Fields]	34,147

PubMed	Search block: Long-term care (C)		19. Jan 2022
Search #	Query	Search string	Results
#24	Long-term care	"long term care"[MeSH Terms] OR ("long term"[All Fields] AND "care"[All Fields]) OR "long term care"[All Fields] OR ("long"[All Fields] AND "term"[All Fields] AND "care"[All Fields]) OR "long term care"[All Fields]	158,645
#25	Primary care	"primary health care"[MeSH Terms] OR ("primary"[All Fields] AND "health"[All Fields] AND "care"[All Fields]) OR "primary health care"[All Fields] OR ("primary"[All Fields] AND "care"[All Fields]) OR "primary care"[All Fields]	519,348
#26	Community healthcare	"community health services"[MeSH Terms] OR ("community"[All Fields] AND "health"[All Fields] AND "services"[All Fields]) OR "community health services"[All Fields] OR ("community"[All Fields] AND "healthcare"[All Fields]) OR "community healthcare"[All Fields]	453,397
#27	Community dwelling	"independent living"[MeSH Terms] OR ("independent"[All Fields] AND "living"[All Fields]) OR "independent living"[All Fields] OR ("community"[All Fields] AND "dwelling"[All Fields]) OR "community dwelling"[All Fields]	55,793
#28	Community nursing	("community"[All Fields] AND "nursing"[All Fields]) OR "community nursing"[All Fields]	85,995
#29	Home healthcare	("home environment"[MeSH Terms] OR ("home"[All Fields] AND "environment"[All Fields]) OR "home environment"[All Fields] OR "home"[All Fields] AND ("delivery of health care"[MeSH Terms] OR ("delivery"[All Fields] AND "health"[All Fields] AND "care"[All Fields]) OR "delivery of health care"[All Fields] OR "healthcare"[All Fields] OR "healthcare s"[All Fields] OR "healthcares"[All Fields])	68,971
#30	Home nursing	"home nursing"[MeSH Terms] OR ("home"[All Fields] AND "nursing"[All Fields]) OR "home nursing"[All Fields]	72,058

#31	Nursing home	"nursing homes"[MeSH Terms] OR ("nursing"[All Fields] AND "homes"[All Fields]) OR "nursing homes"[All Fields] OR ("nursing"[All Fields] AND "home"[All Fields]) OR "nursing home"[All Fields]	99,292
#32	Combination:	<b>#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR 30 OR #31</b>	1,155,165

PubMed	Combination of blocks		19. Jan 2022
Search #	Query	Search string	Results
#33	Combination (P):	<b>#4 OR #14 OR #22</b>	8,752,419
#34	Combination (PIC):	<b>#23 AND #32 AND #33</b>	11,877

For peer review only

# BMJ Open

## Nursing, Frailty, Functional Decline and Models of Care in Relation to Older People Receiving Long-term Care: A Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061303.R2
Article Type:	Protocol
Date Submitted by the Author:	26-Jul-2022
Complete List of Authors:	Flyum, Ida; Karlstad University Faculty of Health Science and Technology, Institute of Health Sciences, Department of Nursing; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing Gjevjon, Edith; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing Josse-Eklund, Anna; Karlstad University Faculty of Health Science and Technology, Institute of Health Sciences, Department of Nursing Lærum-Onsager, Ellisiv; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing Borglin, Gunilla; Lovisenberg Diaconal University College, Department of Bachelor's in Nursing
<b>Primary Subject Heading</b>:	Nursing
Secondary Subject Heading:	Health services research, Geriatric medicine
Keywords:	GERIATRIC MEDICINE, PRIMARY CARE, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

# Nursing, Frailty, Functional Decline and Models of Care in Relation to Older People Receiving Long-term Care: A Scoping Review Protocol

*Ida Røed Flyum<sup>1,2</sup> RN, MNsc, PhD-candidate, Edith Roth Gjevjon<sup>1</sup> RN, MNsc, PhD, Anna Josse-Eklund<sup>2</sup> RN, DN, PhD, Ellisiv Lærum-Onsager<sup>1</sup> RN, MSc, PhD, Gunilla Borglin<sup>1</sup> RN, MSc, PhD, Professor in Nursing*

<sup>1</sup>Lovisenberg Diaconal University College, Department of Bachelor's in Nursing.  
Lovisenberggata 15B, NO-0456 Oslo, Norway

<sup>2</sup>Karlstad University, Faculty of Health, Nature and Technical Science, Institute of Health Sciences, Department of Nursing, Universitetsgatan 2, 651 88 Karlstad, Sweden

ORCID:

Ida Røed Flyum: <https://orcid.org/0000-0002-6256-4245>

Edith Roth Gjevjon: <https://orcid.org/0000-0002-9656-522X>

Anna Josse-Eklund: <https://orcid.org/0000-0002-1192-9697>

Ellisiv Lærum-Onsager: <https://orcid.org/0000-0001-9097-6100>

Gunilla Borglin: <https://orcid.org/0000-0002-7934-6949>

**Corresponding author:**

Ida Røed Flyum,  
Lovisenberggata 15B,  
NO-0456 Oslo, Norway  
[Ida.r.flyum@ldh.no](mailto:Ida.r.flyum@ldh.no)

Word count: 3469

## ABSTRACT

**Introduction:** Older people receiving healthcare in long-term care contexts (e.g., home healthcare, sheltered housing and nursing home contexts) are especially vulnerable to developing frailty and functional decline. Considering the negative effects associated with these conditions and the possibility of preventing them from progressing, it is vital that nurses possess a broad knowledge base related to them. Particularly as prevention related to these conditions lies well within their remit. Such knowledge could guide the development of effective models of care, ensuring continuity and, hence, quality of care. Our objective will be to review published literature on existing models of care targeting frailty and/or functional decline and how these conditions are described by older people themselves, significant others, and nurses in relation to long-term care.

**Methods and analysis:** The scoping review will be conducted in accordance with Arksey and O'Malley's methodological framework. Recent methodological developments will be considered. PubMed, CINAHL and PsycINFO will be searched. Eligibility criteria will be peer-reviewed papers and written in English. All types of study designs will be eligible and included papers will be quality- and ethically assessed. The PRISMA-P checklist for protocols and the PRISMA-ScR checklist were followed in this paper.

**Ethics and dissemination:** As the study outlined in this protocol is a scoping review no ethics approval was needed for this protocol nor for the upcoming study. The findings will be published in an open-access, peer-reviewed journal. Additionally, the findings will guide a research project following the Medical Research Council's framework for developing and evaluating complex interventions. Thus, supporting us in developing a model of care related to the detection and prevention of frailty and/or functional decline among older people in a long-term care context.

**Registration details:** Open Science Framework, [10.17605/OSF.IO/FNHSA](https://doi.org/10.17605/OSF.IO/FNHSA).

### Strengths and limitations of this study:

- Designing and reporting the protocol and upcoming scoping review in accordance with the PRISMA checklists will ensure the transparency, reliability and rigour of the review.
- The support of an information specialist in developing a comprehensive search strategy will ensure a higher probability of identifying eligible papers.
- Using a review team of five individuals will ensure independent assessment by two reviewers in all stages, as well as the opportunity to consult with a third person if necessary.
- Adopting a joint strategy of quality assessment and comprehensive overview may contribute to both identifying the gaps in the literature, as well as increasing the uptake and relevance of the results for practice and policy makers.
- Not including stakeholders in the conception and designing of this review might be a limitation.

## INTRODUCTION

Considering the potential adverse health outcomes of frailty and functional decline,[1, 2] as well as the potential reversibility of these conditions,[3] there is an undeniable need for effective models of care for the early detection and prevention of frailty and functional decline among older people in long-term care contexts (e.g., home healthcare, sheltered housing and nursing home contexts).[4, 5] Preventing frailty and functional decline as a part of a healthy ageing strategy is a globally important aim and has been promoted by both the European Commission and World Health organisation (WHO).[6, 7] Despite their global attention, both conditions are repeatedly described as closely related, and the terms are often used interchangeably.[8, 9] The nature of their relationship has been debated, even though the consensus appears to be that frailty predicts functional decline and disability.[3, 10] Our upcoming scoping review will depart from the idea of such a relationship.

It is well known that we live longer and, hence, are at an increased risk of multimorbidity, polypharmacy and the presentation of complex symptoms.[11] This indicates that the number of older people with frailty and at risk of functional decline[8, 11, 12] also is likely to substantially increase. The prevalence of frailty tends to vary, which might be because of the use of numerous definitions and screening instruments but also because frailty tends to increase with age.[13] Among community-dwelling older people (60+), the prevalence of frailty has been estimated to be between 2.6% and 60%[14, 15] and for nursing home patients between 19% and 75.6%.[15, 16] Frailty has also been associated with increased healthcare-related costs.[17] The early detection and preventative healthcare measures targeting these two conditions in long-term care contexts seems vital both for the healthcare offered and the quality of care for older patients. Unfortunately, such measures are challenging for several reasons.

First, older people receiving healthcare services in long-term care contexts are a heterogeneous population; they range from being relatively independent and in need of low-intensity care to being dependent on a range of activities of daily living (ADL) and in need of high intensity care.[11] Furthermore, it is fair to assume that through, for example, informal caregivers, these individuals' deteriorations might be compensated for and delayed over a longer period of time, thereby masking their actual care needs. This complex composition within both the population and the individuals themselves – masking actual care needs – increases the risk of adverse health outcomes because of the difficulties to detect the conditions.

1  
2  
3 Second, there is a growing number of older people ageing in place—that is, staying in their own  
4 homes.[18] This trend is believed to contribute to appropriate care at a lower cost compared  
5 with institutionalised care.[19, 20] Furthermore, according to Boland, et al. [21] there is  
6 insufficient evidence related to health-related outcomes to recommend either institutionalised  
7 care or home healthcare. Emphasising the preference of the older person when considering  
8 moving the locations of care should be taken into account. Research implies that most older  
9 people value their independence and prefer to remain in a familiar environment where they feel  
10 like they belong.[18] Stressing the importance of detecting and preventing conditions such as  
11 frailty and/or functional decline early on in this population. This might result in positive  
12 implications when it comes to their possibility for healthy ageing[6, 22] and contribute to more  
13 older people having the choice of ageing in place.[18, 22, 23] However, it has been documented  
14 that long-term care services experience limitations related to the following: time with patients,  
15 number of healthcare staff with adequate competence, collaboration with other professions,  
16 guidelines and protocols for care, high rates of sick leave, part-time workers and nurse  
17 retention.[23-25] This might increase the risk of nursing staff (e.g., registered nurses, registered  
18 practical nurses, licensed practical nurses, and nursing assistants/aides)[26]—hereinafter  
19 referred to as nurses—being forced to ration care.[27] This may result in patient monitoring  
20 being less prioritised and a further rationing of care that might lead to the signs and symptoms  
21 related to frailty and/or functional decline going unobserved. This can risk both patient safety  
22 and satisfaction.[28]

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39 Third, a prerequisite for detecting and preventing frailty and/or functional decline is a clear  
40 definition and understanding of the concepts, both medically and clinically. A number of  
41 definitions have been proposed, yet no consensus exists.[9, 29] In the upcoming scoping review,  
42 frailty will be understood in accordance with Clegg et al.'s[30] description as '*a state of*  
43 *vulnerability to poor resolution of homeostasis after a stressor event and is a consequence of*  
44 *cumulative decline in many physiological systems during a lifetime*' (p. 1). A critical point in  
45 the degenerative processes is reached where the homeostatic mechanisms are no longer  
46 sufficient. This results in vulnerability, that is, a seemingly small incidence (new drug or a  
47 'minor' infection), having a disproportionate effect on the individual's health.[30] This then  
48 increases the risk of adverse health outcomes such as falls, hospitalisation, disability and  
49 death.[1, 2] Furthermore, the dependency in ADLs in people with frailty may fluctuate  
50 substantially. This is often referred to as 'unstable disability',[30] and we postulate that such  
51 fluctuating disability could be understood as functional decline.

1  
2  
3  
4  
5 For the upcoming review, functional decline will be defined as a new loss of independence in  
6 self-care activities or as a deterioration in self-care skills, here as measured on an ADL scale  
7 (e.g., bathing, dressing, transferring from bed to chair, using the toilet, etc.) and/or on an  
8 instrumental activities of daily living (IADL) scale (e.g., shopping, housekeeping, preparing  
9 meals, etc.).[31, 32] Functional decline among older people can also result in compromises  
10 beyond ADL for example physical problems such as falls and malnutrition and psychosocial  
11 problems such as depression and delirium.[33] According to Hébert [34] functional decline may  
12 manifest subacutely or acutely. Subacute functional decline slowly develops over time and is  
13 more difficult to detect than acute functional decline, particularly if the patients are not screened  
14 for physical or mental capacity changes. Usually, this is caused by chronic disease or a new,  
15 undetected disease, but it may also arise because of polypharmacy, cognitive decline or a  
16 psychiatric condition. Acute functional decline often manifests in a couple of days to a week  
17 and requires emergent medical attention and hospitalisation. It can be caused by an acute  
18 incident (e.g., infection, fall or stroke), malfunction in compensatory mechanisms of a chronic  
19 condition or a psychological crisis (e.g., death of a significant other or hospital admission).

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33 Among healthcare professionals, nurses are the largest professional group. They are often the  
34 first point of contact, and they are also the group that spends the most time with the patients.  
35 Thus, the management of care, including detecting and preventing the signs and symptoms of  
36 frailty and/or functional decline, lies both within their remit and range of responsibilities.  
37 Despite this, we have not been able to identify any published reviews summarising the evidence  
38 within this field. Instead, recent reviews have focused on areas such as the effect of  
39 interventions[35-38] and screening tools.[39-41] Furthermore, we might argue that to develop  
40 effective models of care related to these conditions, it is critical to understand how frailty and  
41 functional decline might be described beyond our medical understanding and by important  
42 stakeholders.

43  
44  
45  
46  
47  
48  
49  
50  
51 Additionally, nurses are expected to provide a diverse range of healthcare services, and one of  
52 their functions is to assess, diagnose, intervene and evaluate a patient's personal health  
53 needs.[42, 43] Consequently, nursing staff can play a major role in delivering a safe and  
54 evidence-based practice that involves detecting and establishing appropriate care actions for  
55 older people, regardless of their conditions. Working in accordance with structured and logical  
56 (effective) models of care to detect, prevent or postpone frailty and/or functional decline among  
57  
58  
59  
60

1  
2  
3 older people in long-term care is vital. Hence, our objective will be to review the literature on  
4 existing models of care, frameworks, patient care pathways and/or clinical practice guidelines  
5 targeting frailty and/or functional decline, as well as how these two conditions are described by  
6 key stakeholders (e.g., older people themselves, their significant others, and nurses) in relation  
7 to long-term care.  
8  
9  
10  
11  
12

### 13 **METHOD AND ANALYSIS**

14  
15 The upcoming scoping review will be conducted in accordance with Arksey and O'Malley's  
16 [44] methodological frameworks for conducting scoping studies stage 1-5. Thus, leaving out  
17 the optional stage regarding consultation with stakeholders and experts. Additionally,  
18 methodological developments will be considered, that is, Levac, et al. [45] and Daudt, et al.  
19 [46] As the topic of interest for the upcoming study is broad and complex in nature, in addition  
20 to the lack of previously comprehensive reviews, a scoping review design is deemed  
21 appropriate.[44] This design allows for inclusion of a diverse range of study designs and papers  
22 of differing levels of quality. Furthermore, the iterative methodological process offers us the  
23 opportunity to revise our research questions (i.e., remove, amend, or add questions) as we gain  
24 more familiarity with the research area.[44] During the search processes the final inclusion and  
25 exclusion criteria will be decided upon. This might mean excluding certain conditions or  
26 specific forms of care (e.g., palliative care or stroke), change of population and specification of  
27 the context. This flexibility is important when reviewing a topic as broad, uncharted, and  
28 complex as ours. The iterative approach allows us to start out with broad research questions.  
29 This is favourable as we aim to summarise the research findings in our research area as well as  
30 to create an overview of both gaps in the literature and of areas which have been thoroughly  
31 researched.[44] The included papers will undergo ethical and critical appraisal,[45, 47, 48]  
32 relevant data will be extracted,[45, 49] and data answering the review questions will be  
33 analysed by content analysis.[50]  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 This protocol will utilise the Preferred Reporting Items for Systematic Reviews and Meta-  
51 Analyses Extension for Scoping Reviews (PRISMA-ScR) checklist,[51] as well as the  
52 PRISMA-P checklist for reporting protocols (Supplementary file 1-2),[52] which is  
53 recommended for scoping reviews and systematic reviews.[53] As recommended, the  
54 upcoming review is registered in the Open Science Framework (OSF) (registration number  
55 [10.17605/OSF.IO/FNHSA](https://doi.org/10.17605/OSF.IO/FNHSA). Registered and last updated on 30 June 2021). Following this  
56 registration, the preparations for the review started with the writing and submission of this  
57  
58  
59  
60

protocol, including preliminary searches. Submitted in January 2022. The database searches were finalised and run in late June 2022. All searches were thereafter downloaded to Rayyan and the inclusion- and exclusion process of eligible papers will start mid-August. The tentative end time for the scoping review will be December 2022 – January 2023.

### Stage 1: Identifying the research question

In accordance with Arksey and O'Malley [44] tentative and broad research questions were formulated following the PICoS (Population, Phenomenon of Interest, Context and Study design) framework (Table 1). In accordance with the iterative approach of a scoping review, the tentative research questions may be reformulated as we gain familiarity with the research area.[44]

- What models of care, frameworks, patient care pathways and/or clinical practice guidelines targeting the detection and prevention of frailty and subsequently functional decline among older people are described in relation to long-term care?
- How is the condition of frailty described by key stakeholders in long-term care?
- How is the condition of functional decline described by key stakeholders in long-term care?

Furthermore, subquestions will encompass the following: By whom are the questions in the literature answered, in what specific contexts, in relation to whom or what? Which research designs have been utilised? How is the methodological quality appraised?

**Table 1.** PICoS framework for determination of eligibility of review questions

Criteria	Determinants
<b>Population</b>	Older people (65+ years) Significant others Nurses[26]
<b>Phenomenon of Interest</b>	Descriptions of models of care, frameworks, patient care pathways and/or clinical practice guidelines targeting the detection and prevention of frailty and/or functional decline among older people  Descriptions of frailty and/or functional decline among older people
<b>Context</b>	Long-term care, e.g., home healthcare, sheltered housing and nursing homes[4, 5]
<b>Study design</b>	All study designs

## Stage 2: Identifying relevant studies

Systematic searches will be conducted in PubMed, CINAHL and PsycINFO. These databases cover the majority of the published, peer-reviewed health service research. The search strategies will be constructed following the PICoS categories and will be tailored to each database. To achieve a comprehensive search strategy with sensitivity and specificity, we will include both controlled subject headings such as MeSH,[54] as well as keywords and synonyms. No time limitation will be implemented because of the lack of earlier reviews and the aim to comprehensively map the area of interest.[44] A preliminary search strategy was constructed for PubMed in collaboration with an information specialist at Karlstad University (Supplementary File 3, last updated on 19 January 2022). Additionally, the reference lists of all the included papers will be searched.[44, 54, 55] To ensure transparency in the iterative process, the first author will keep a logbook throughout the entire project to track amendments from this protocol and other decisions made, including the rationale.[55, 56] Considering what types of research will most likely be relevant for answering our research questions, as well as the time and resources needed searching for grey literature,[55] we have decided to include only published, peer-reviewed research.

## Stage 3: Study selection

To ensure consistency, reliability and validity in the selection process, eligibility criteria will be constructed.[45] A tentative summary of the eligibility criteria is described below. Still, in accordance with the iterative process, the eligibility criteria might be refined as familiarity with the field increases and can then be applied to all citations post hoc.[44]

Using the eligibility criteria, two independent reviewers will assess the relevance of all titles and abstracts in the search results. The full text of the relevant papers, as well as those where relevance is unclear, will be assessed for inclusion[44] by two reviewers.[45, 46] Meetings will be held regularly to address any uncertainties.[45] Disagreements will be resolved through discussion and, if necessary, consultation with a third reviewer. The selection process will be documented using the PRISMA flowchart[57] (Figure 1). The data programme Rayyan will be utilised using the option 'blind on' to ensure an independent review.[58]

Insert --- Figure 1. about here ---

The eligibility criteria relate to the categories in PICoS, as well as the research type, language and ethical considerations. The population will be limited to older people, their significant others, and nurses. Older people will be defined as all people over the age of 65 years, considering that this is a standard cut-off for older people in most research and databases today. Significant others are tentatively defined as individuals with a close relationship to the older person, not defined by kinship or by being an unpaid carer. As previously stated, nurses will be defined as nursing staff (e.g., registered nurses, registered practical nurses, licensed practical nurses, and nursing assistants/aides).[26] Because there exists no consensus definition of frailty or functional decline, we will use the definitions presented in the introduction of this protocol as the inclusion criteria. The context will be defined as long-term care contexts, for example, home healthcare, sheltered housing and nursing homes.[4, 5] All study designs will be included. Because the aim of the review is to summarise evidence from published, peer-reviewed research, we will exclude research types not complying with these parameters, such as letters to the editor and discussion papers. Considering time and resources, we will only include papers that do not need translation, that is, those in English. There is a rising appreciation of the contribution that ethical quality assessment in reviews may have on sustainable and ethical research.[47, 48] To contribute to this work, we have constructed a tentative list of the ethical requirements for the included papers, as influenced by Weingarten, et al. [47] (Table 2). Depending on the total number of eligible papers and the overall methodological and ethical quality, a decision regarding excluding papers of subpar standards will be made.

**Table 2.** Ethical requirements

Was the study approved by an ethical research committee?	Yes/No
Was informed consent retrieved from all participants?	Yes/No
Were the personal data/transcriptions/recordings properly managed, stored and disposed off?	Yes/No
Was the relevance of the study clearly justified?	Yes/No
Was any conflict of interests or funding declared?	Yes/No

## Stage 4: Charting the data

A data charting form will be iteratively developed to facilitate the systematic charting of data. Tentative data charting items are shown in Box 1, which will be iteratively developed throughout the review process. Two reviewers will develop and independently test the form on the first five to ten relevant papers.[45, 49] Thereafter, two independent reviewers will apply the form to all included papers. Disagreements will be resolved by discussion with a third review team member.

### Box. 1 Tentative data charting items

<b>Full reference</b> (including authors, year of publication, journal, etc.)
<b>Title</b>
<b>Aim, objective and/or research question</b>
<b>Population and participant characteristics</b> (e.g., total number of participants and number per subgroup, i.e., older people, significant others, and nurses. Age range for the older people and type of significant other, as for example spouse, child, or neighbour. As well as type of nurse, such as registered nurse or nursing assistant)
<b>Phenomenon of Interest</b> (e.g., frailty, functional decline, both conditions, models of care, practice guidelines)
<b>Study context and country</b>
<b>Sampling method</b>
<b>Study design</b> (e.g., type of qualitative, quantitative, or mixed/multiple methods)
<b>Data collection method</b> (e.g., individual interviews, focus groups or survey)
<b>Data analysis</b> (e.g., type of thematic analysis, content analysis, descriptive numerical analysis)
<b>Relevant findings</b> (e.g., themes, categories, numerical data, and outcomes, types of models of care, possible theoretical underpinnings)
<b>Quality assessment</b> (the Critical Appraisal Skills Programme checklists[59] or the mixed methods appraisal tool[60])
<b>Ethical assessment</b> (see Table 2[47] [48])

Quality appraisal in scoping reviews is a topic of debate, with researchers both for[45, 46, 61] and against it.[44, 49] Despite this all the included papers will be quality assessed but included regardless of the results. No weighting of the evidence will be done;[44] rather, a quality assessment will be utilised to identify potential gaps in the literature related to high-quality research.[45] The quality assessment will be conducted by two independent reviewers using the

1  
2  
3 checklists from the Critical Appraisal Skills Programme (CASP).[59] For mixed method  
4 studies, the mixed method appraisal tool will be applied.[60]  
5  
6  
7

### 8 **Stage 5: Collating, summarising and reporting the results**

9  
10 The charted data including the relevant findings from each included paper will be presented in  
11 both a schematical overview and as a narrative account. Numerical analysis of the quantitative  
12 data will be descriptive and focus on the nature, extent and distribution of the data. How the  
13 results are presented will depend on the findings (e.g., tables, chart, figures).[49] The qualitative  
14 data will most likely be analysed using qualitative content analysis,[50] as recommended by  
15 Levac, et al. [45] Still, considering the iterative methodologically approach we might decide to  
16 change the method for qualitative analysis as we gain familiarity with the evidence. Irrespective  
17 of which method of analysis is chosen the focus will be on the manifest content. Using a  
18 descriptive approach and focusing on manifest content entails a very low degree of  
19 interpretation.[62] This is in accordance with the aim of summarising—not synthesising—  
20 evidence in a scoping review.[44] Additionally, the PAGER (Patterns, Advances, Gaps,  
21 Evidence for practice and Research recommendations) reporting guidelines framework for  
22 scoping reviews will be used to secure the quality of our reporting.[63] Two reviewers will be  
23 responsible for this stage, and regular meetings will be conducted with the whole review team  
24 where decisions related to analysis and presentation of findings will be discussed and decided  
25 upon.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Patient and public involvement**

41 No patients were involved in the conception or design of the upcoming review.  
42  
43  
44

### 45 **ETHICS AND DISSEMINATION**

46  
47 Despite reviews being excluded from ethical assessment by ethical review authorities,[64-66]  
48 the need for ethical considerations when conducting reviews has been highlighted by  
49 Vergnes, et al. [48] and Weingarten, et al. [47] Vergnes, et al. [48] offers the following  
50 arguments pro ethical assessment, i) raising awareness of the importance of upholding the  
51 high ethical standard in research with humans, ii) not basing practice on trials not following  
52 ethical principles, iii) respecting the conflict of interest statement as well as the financial  
53 disclosure, iv) discouraging publication of non-ethical research under the cover of “systematic  
54 review”, v) respecting confidentiality and informed consent. Additionally, as there is no  
55  
56  
57  
58  
59  
60

consensus on how to assess ethical issues in reviews Weingarten, et al. [47] have proposed the use of standardised protocols for assessing ethical aspects (e.g., Table 2). We will contribute to this by considering the ethical standards of all eligible papers.

Furthermore, to ensure an effective literature review, as well as avoid research waste,[67] we have conducted a thorough exploratory search to assess the need for the upcoming review. The ethical importance of writing this protocol should also be mentioned because protocols alongside the precise logging of amendments in the final review manuscript are an important part of making our review transparent to criticism.

The scoping review will be published in a peer-reviewed, open-access journal. Tentatively, the findings will be reported by winter 2022. Additionally, the findings will be utilised in a research project following the Medical Research Council's framework for developing and evaluating complex interventions[68] to inform the development of a model of care related to the detection and prevention of frailty and/or functional decline among older people in a long-term care context.

## ACKNOWLEDGEMENTS

We would like to thank Annelie Ekberg-Andersson, Information Specialist at Karlstad University, for her contribution to the search strategies presented in this protocol.

## AUTHORS' CONTRIBUTIONS

IRF, GB, ERG, AJ-E and EL-O were responsible for the study's inception and design. IRF was responsible for drafting the first version of the manuscript. GB, ERG, AJ-E and EL-O were responsible for the critical revision of the paper and for adding important intellectual content. GB supervised the study. All authors read and approved the final manuscript.

## FUNDING STATEMENT

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

## COMPETING INTERESTS STATEMENT

The authors of this scoping review protocol declare no competing interests in connection with this manuscript.

## LICENCE STATEMENT

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

**Figure 1.** PRISMA-flowchart: Overview of the study selection process

## REFERENCES

1. Fried LP, Tangen CM, Walston J, et al. Frailty in Older Adults: Evidence for a Phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56(3):M146-M57. doi: 10.1093/gerona/56.3.M146
2. Vermeiren S, Vella-Azzopardi R, Beckwée D, et al. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. *J Am Med Dir Assoc* 2016;17(12):1163.e1-63.e17. doi: 10.1016/j.jamda.2016.09.010
3. Sezgin D, Liew A, O'Donovan MR, et al. Pre-frailty as a multi-dimensional construct: A systematic review of definitions in the scientific literature. *Geriatr Nurs* 2020;41(2):139-46. doi: 10.1016/j.gerinurse.2019.08.004
4. National Institute on Ageing. Enabling the Future Provision of Long-Term Care in Canada. . Toronto, 2019.
5. National Institute on Aging. What is Long-Term Care? 2017 [Available from: <https://www.nia.nih.gov/health/what-long-term-care>].
6. World health organization. Decade of Healthy Ageing 2020-2030, 2020.
7. Cano A, Dargent G, Carriazo A, et al. Tackling frailty and functional decline: Background of the action group A3 of the European innovation partnership for active and healthy ageing. *Maturitas* 2018;115:69-73. doi: 10.1016/j.maturitas.2018.06.009
8. Beaton K, McEvoy C, Grimmer K. Identifying indicators of early functional decline in community-dwelling older people: A review. *Geriatr Gerontol Int* 2014;15(2):133-40. doi: 10.1111/ggi.12379
9. Sezgin D, O'Donovan M, Cornally N, et al. Defining frailty for healthcare practice and research: A qualitative systematic review with thematic analysis. *Int J Nurs Stud* 2019;92:16-26. doi: 10.1016/j.ijnurstu.2018.12.014
10. Church S, Rogers E, Rockwood K, et al. A scoping review of the Clinical Frailty Scale. *BMC Geriatr* 2020;20:1-18. doi: 10.1186/s12877-020-01801-7
11. Roller-Wirnsberger R, Singler K, Polidori MC. Learning Geriatric Medicine: A Study Guide for Medical Students: Springer International Publishing AG 2018.

12. Fried LP, Ferrucci L, Darer J, et al. Untangling the Concepts of Disability, Frailty, and Comorbidity: Implications for Improved Targeting and Care. *J Gerontol A Biol Sci Med Sci* 2004;59(3):M255-M63. doi: 10.1093/gerona/59.3.M255
13. Kehler DS, Ferguson T, Stammers AN, et al. Prevalence of frailty in Canadians 18–79 years old in the Canadian Health Measures Survey. *BMC Geriatr* 2017;17 doi: 10.1186/s12877-017-0423-6
14. Collard RM, Boter H, Schoevers RA, et al. Prevalence of Frailty in Community-Dwelling Older Persons: A Systematic Review. *J Am Geriatr Soc* 2012;60(8):1487-92. doi: 10.1111/j.1532-5415.2012.04054.x
15. O'Caomh R, Galluzzo L, Rodríguez-Laso Á, et al. Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis. *Ann Ist Super Sanità* 2018;54(3):226-38. doi: 10.4415/ANN\_18\_03\_10
16. Kojima G. Prevalence of Frailty in Nursing Homes: A Systematic Review and Meta-Analysis. *J Am Med Dir Assoc* 2015;16(11):940-45. doi: 10.1016/j.jamda.2015.06.025
17. Kojima G. Increased healthcare costs associated with frailty among community-dwelling older people: A systematic review and meta-analysis. *Arch Gerontol Geriatr* 2019;84 doi: 10.1016/j.archger.2019.06.003
18. Pani-Harreman KE, Bours GJJW, Zander I, et al. Definitions, key themes and aspects of 'ageing in place': a scoping review. *Ageing Soc* 2021;41:2026-59. doi: 10.1017/S0144686X20000094
19. Genet N, Boerma W, Kroneman M, et al. Home care across Europe: Current structure and future challenges. *European Observatory on Health Systems and Policies* 2012
20. Horner B, Boldy DP. The benefit and burden of "ageing-in-place" in an aged care community. *Aust Health Rev* 2008;32(2):356-65. doi: 10.1071/ah080356
21. Boland L, Légaré F, Perez MMB, et al. Impact of home care versus alternative locations of care on elder health outcomes: an overview of systematic reviews. *BMC Geriatr* 2017;17:1-15. doi: 10.1186/s12877-016-0395-y
22. Norwegian Ministry of Health and Care Services. A full life - all your life: A Quality Reform for Older Persons. 2019
23. Spasova S, Baeten R, Coster S, et al. Challenges in long-term care in Europe - A study of national policies 2018. Brussels: European Commission: European Social Policy Network (ESPN), 2018.
24. Valizadeh L, Zamanzadeh V, Saber S, et al. Challenges and Barriers Faced by Home Care Centers: An Integrative Review. *Medical - Surgical Nursing Journal* 2018;7(3):e83486. doi: 10.5812/msnj.83486
25. Organisation for Economic Co-operation and Development (OECD). Health at a Glance 2021: OECD Indicators 2021.
26. Chu CH, McGilton KS, Spilsbury K, et al. Strengthening International Research in Long-Term Care: Recommended Common Data Elements to Support Clinical Staff Training. *Gerontol Geriatr Med* 2021;7:1-17. doi: 10.1177/2333721421999312
27. Kalánková D, Žiaková K, Kurucová R. Approaches to understanding the phenomenon of missed/rationed/unfinished care - a literature review. *Central European Journal of Nursing and Midwifery* 2019;10(1):1005-16. doi: 10.15452/CEJNM.2019.10.0007
28. Kalánková D, Kirwan M, Bartoníčková D, et al. Missed, rationed or unfinished nursing care: A scoping review of patient outcomes. *J Nurs Manag* 2020;28(8):1783-97. doi: 10.1111/jonm.12978
29. Junius-Walker U, Onder G, Soleymani D, et al. The essence of frailty: A systematic review and qualitative synthesis on frailty concepts and definitions. *Eur J Intern Med* 2018;56:3-10. doi: 10.1016/j.ejim.2018.04.023


- 1  
2  
3 30. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. *Lancet* 2013;381(9868):752-62.  
4 doi: 10.1016/S0140-6736(12)62167-9
- 5 31. Fortinsky RH, Covinsky KE, Palmer RM, et al. Effects of functional status changes before  
6 and during hospitalization on nursing home admission of older adults. *J Gerontol A*  
7 *Biol Sci Med Sci* 1999;54(10):M521-6. doi: 10.1093/gerona/54.10.m521
- 8 32. Hébert R, Brayne C, Spiegelhalter D. Factors Associated with Functional Decline and  
9 Improvement in a Very Elderly Community-dwelling Population. *Am J Epidemiol*  
10 1999;150(5):501-10. doi: 10.1093/oxfordjournals.aje.a010039
- 11 33. de Vos AJBM, Asmus-Szepesi KJE, Bakker TJEM, et al. Integrated approach to prevent  
12 functional decline in hospitalized elderly: the Prevention and Reactivation Care  
13 Program (PReCaP). *BMC Geriatr* 2012;12 doi: 10.1186/1471-2318-12-7
- 14 34. Hébert R. Functional decline in old age. *CMAJ* 1997;157(8):1037-45.
- 15 35. Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Effectiveness of interventions to  
16 prevent pre-frailty and frailty progression in older adults: a systematic review. *JBIR*  
17 *Database System Rev Implement Rep* 2018;16(1):140-232. doi: 10.11124/JBISRIR-  
18 2017-003382
- 19 36. Travers J, Romero-Ortuno R, Bailey J, et al. Delaying and reversing frailty: a systematic  
20 review of primary care interventions. *Br J Gen Pract* 2019;69(678):e61-e69. doi:  
21 10.3399/bjgp18X700241
- 22 37. Verstraten CCJMM, Metzelthin SF, Schoonhoven L, et al. Optimizing patients' functional  
23 status during daily nursing care interventions: A systematic review. *Res Nurs Health*  
24 2020;43(5):478-88. doi: 10.1002/nur.22063
- 25 38. Mareschal J, Genton L, Collet T-H, et al. Nutritional Intervention to Prevent the  
26 Functional Decline in Community-Dwelling Older Adults: A Systematic Review.  
27 *Nutrients* 2020;12(9):1-21. doi: 10.3390/nu12092820
- 28 39. Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Predicting risk and outcomes for frail  
29 older adults: an umbrella review of frailty screening tools. *JBIR Database System Rev*  
30 *Implement Rep* 2017;15(4):1154-208. doi: 10.11124/jbisrir-2016-003018
- 31 40. Faller JW, Pereira DdN, de Souza S, et al. Instruments for the detection of frailty  
32 syndrome in older adults: A systematic review. *PLoS One* 2019;14(4):e0216166. doi:  
33 10.1371/journal.pone.0216166
- 34 41. Roedl KJ, Wilson LS, Fine J. A systematic review and comparison of functional  
35 assessments of community-dwelling elderly patients. *J Am Assoc Nurse Pract*  
36 2016;28(3):160-9. doi: 10.1002/2327-6924.12273
- 37 42. Henderson V. *The Nature of Nursing a Definition and its Implications for Practice,*  
38 *Research, and Education: Macmillan* 1966.
- 39 43. Richards DA, Borglin G. 'Shitty nursing' – The new normal? *Int J Nurs Stud*  
40 2019;91:148-52. doi: 10.1016/j.ijnurstu.2018.12.018
- 41 44. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc*  
42 *Res Methodol* 2005;8(1):19-32. doi: 10.1080/1364557032000119616
- 43 45. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology.  
44 *Implement Sci* 2010;5:69. doi: 10.1186/1748-5908-5-69
- 45 46. Daudt HML, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large,  
46 inter-professional team's experience with Arksey and O'Malley's framework. *BMC*  
47 *Med Res Methodol* 2013;13:48. doi: 10.1186/1471-2288-13-48
- 48 47. Weingarten MA, Paul M, Leibovici L. Assessing ethics of trials in systematic reviews.  
49 *BMJ* 2004;328:1013-14. doi: 10.1136/bmj.328.7446.1013
- 50 48. Vergnes J-N, Marchal-Sixou C, Nabet C, et al. Ethics in systematic reviews. *J Med Ethics*  
51 2010;36(12):771-74. doi: 10.1136/jme.2010.039941
- 52  
53  
54  
55  
56  
57  
58  
59  
60

49. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBIEvid Synth* 2020;18(10):2119-26. doi: 10.11124/JBIES-20-00167
50. Elo S, Kyngäs H. The qualitative content analysis process. *J Adv Nurs* 2008;62(1):107-15. doi: 10.1111/j.1365-2648.2007.04569.x
51. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR) : Checklist and Explanation. *Ann Intern Med* 2018;169:467-73. doi: 10.7326/M18-0850
52. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647. doi: 10.1136/bmj.g7647
53. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1
54. Bramer WM, de Jonge GB, Rethlefsen ML, et al. A systematic approach to searching: an efficient and complete method to develop literature searches. *J Med Libr Assoc* 2018;106(4):531-41. doi: 10.5195/jmla.2018.283
55. Booth A. Searching for qualitative research for inclusion in systematic reviews: a structured methodological review. *Syst Rev* 2016;5:74. doi: 10.1186/s13643-016-0249-x
56. Pollock D, Davies EL, Peters MDJ, et al. Undertaking a scoping review: A practical guide for nursing and midwifery students, clinicians, researchers, and academics. *J Adv Nurs* 2021;77(4):2102-13. doi: 10.1111/jan.14743
57. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71
58. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. *Syst Rev* 2016;5:210. doi: 10.1186/s13643-016-0384-4
59. Critical Appraisal Skills Programme. CASP Checklists n.d. [Available from: <https://casp-uk.net/casp-tools-checklists/>]
60. Hong QN, Pluye P, Fàbregues S, et al. Improving the content validity of the mixed methods appraisal tool: a modified e-Delphi study. *J Clin Epidemiol* 2019;111:49-59. doi: 10.1016/j.jclinepi.2019.03.008
61. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. *Health Info Libr J* 2009;26(2):91-108. doi: 10.1111/j.1471-1842.2009.00848.x
62. Lindgren B-M, Lundman B, Graneheim UH. Abstraction and interpretation during the qualitative content analysis process. *Int J Nurs Stud* 2020;108:103632-32. doi: 10.1016/j.ijnurstu.2020.103632
63. Bradbury-Jones C, Aveyard H, Herber OR, et al. Scoping reviews: the PAGER framework for improving the quality of reporting. *Int J Soc Res Methodol* 2021:1-14. doi: 10.1080/13645579.2021.1899596
64. The Ministry of Education and Cultural Affairs. The Act concerning the Ethical Review of Research Involving Humans (SFS number: 2003:460), 2003.
65. the Health Research Act. Act on medical and health research, 2008.
66. Norwegian centre for research data. n.d. [Available from: <https://www.nsd.no>]
67. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *Lancet* 2009;374(9683):86-89. doi: 10.1016/S0140-6736(09)60329-9
68. Skivington K, Matthews L, Simpson SA, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. *BMJ* 2021;374:n2061 doi: 10.1136/bmj.n2061

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. PRISMA-flowchart: Overview of the study selection process



## SUPPLEMENTARY FILE 1

## Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
<b>TITLE</b>			
Title	1	Identify the report as a scoping review.	Title page
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	1
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	3-6
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	5-6
<b>METHODS</b>			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	6

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	8
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Supplementary File 3
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	Box 1

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	9
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	10
<b>RESULTS</b>			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Not applicable for the protocol
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Not applicable for the protocol
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not applicable for the protocol
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Not applicable for the protocol
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Not applicable for the protocol
<b>DISCUSSION</b>			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of	Not applicable for the protocol

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
		evidence available), link to the review questions and objectives, and consider the relevance to key groups.	
Limitations	20	Discuss the limitations of the scoping review process.	Not applicable for the protocol
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	Not applicable for the protocol
<b>FUNDING</b>			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	11

JBIG = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

\* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## SUPPLEMENTARY FILE 2

### PRISMA-P 2015 Checklist

This checklist was retrieved by the authors of this protocol from the PRISMA web page, and is an adapted version of Table 3 in Moher, et al.<sup>52</sup>: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
<b>ADMINISTRATIVE INFORMATION</b>					
<b>Title</b>					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Title page
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Registration</b>	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1 and 6
<b>Authors</b>					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Title page
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	11
<b>Amendments</b>	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7
<b>Support</b>					
Sources	5a	Indicate sources of financial or other support for the review	<input type="checkbox"/>	<input checked="" type="checkbox"/>	11

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
					No funders/sponsors
Sponsor	5b	Provide name for the review funder and/or sponsor	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Not applicable
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Not applicable
<b>INTRODUCTION</b>					
<b>Rationale</b>	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	3-6
<b>Objectives</b>	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	6
<b>METHODS</b>					
<b>Eligibility criteria</b>	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
<b>Information sources</b>	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	7
<b>Search strategy</b>	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Supplementary File 3
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	8

Section/topic	#	Checklist item	Information reported		Page number(s)
			Yes	No	
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
<b>Data items</b>	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Box 1
<b>Outcomes and prioritization</b>	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Box 1
<b>Risk of bias in individual studies</b>	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	9
<b>DATA</b>					
<b>Synthesis</b>	15a	Describe criteria under which study data will be quantitatively synthesized	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	10
<b>Meta-bias(es)</b>	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<b>Confidence in cumulative evidence</b>	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

1 by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
 26/bmjopen-2022-061303 on 23 August 2022. Downloaded from <http://bmjopen.bmj.com/> on May 15, 2025 at Department GEZ-LTA  
 ErasmusHogeschool

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## SUPPLEMENTARY FILE 3

Tentative search strategy: PubMed

Last updated on: 19.01.22

**Question 2:** How is the concept of frailty described and understood by older people, their significant others, and nurses in long-term care contexts?

PubMed	Search block: Older people (P)		19. Jan 2022
Search #	Query	Search string	Results
#1	Aged	"aged"[MeSH Terms] OR "aged"[All Fields]	5,765,926
#2	Elderly	"aged"[MeSH Terms] OR "aged"[All Fields] OR "elderly"[All Fields] OR "elderlies"[All Fields] OR "elderly s"[All Fields] OR "elderlys"[All Fields]	5,823,455
#3	Older	"older"[All Fields] OR "olders"[All Fields]	496,898
#4	Combination:	<b>#1 OR #2 OR #3</b>	5,978,243

PubMed	Search block: Significant others (P)		19. Jan 2022
Search #	Query	Search string	Results
#5	Significant others	"significant"[All Fields] AND "other*"[All Fields]	763,016
#6	Informal caregivers	"caregivers"[MeSH Terms] OR "caregiver*"[All Fields] OR ("informal"[All Fields] AND "caregiver*"[All Fields])	92,958
#7	Family	"family"[MeSH Terms] OR "family"[All Fields] OR "families"[All Fields] OR "family s"[All Fields] OR "familys"[All Fields]	1,542,673
#8	Relatives	"relative"[All Fields] OR "relatives"[All Fields] OR "relative s"[All Fields]	984,365
#9	Family caregivers	"caregivers"[MeSH Terms] OR "caregiver*"[All Fields] OR ("family"[All Fields] AND "caregiver*"[All Fields])	92,958
#10	Spouses	"spouse s"[All Fields] OR "spouses"[MeSH Terms] OR "spouses"[All Fields] OR "spouse"[All Fields]	34,339
#11	Husbands	"husband s"[All Fields] OR "husband"[All Fields] OR "husbands"[All Fields]	14,379
#12	Wives	"wife"[All Fields] OR "wives"[All Fields] OR "wife s"[All Fields]	11,491
#13	Next-of-kin	"Next-of-kin"[All Fields]	1,920
#14	Combination:	<b>#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13</b>	3,174,444

PubMed	Search block: Nursing staff (P)		19. Jan 2022
Search #	Query	Search string	Results
#15	Nurse	"nurse s"[All Fields] OR "nurses"[MeSH Terms] OR "nurses"[All Fields] OR "nurse"[All Fields] OR "nurses s"[All Fields]	408,405

#16	Nursing personnel	"nursing staff"[MeSH Terms] OR ("nursing"[All Fields] AND "staff"[All Fields]) OR "nursing staff"[All Fields] OR ("nursing"[All Fields] AND "personnel"[All Fields]) OR "nursing personnel"[All Fields] OR "nurses"[MeSH Terms] OR "nurses"[All Fields] OR ("nursing"[All Fields] AND "personnel"[All Fields])	365,108
#17	Healthcare assistants	"allied health personnel"[MeSH Terms] OR ("allied"[All Fields] AND "health"[All Fields] AND "personnel"[All Fields]) OR "allied health personnel"[All Fields] OR ("healthcare"[All Fields] AND "assistants"[All Fields]) OR "healthcare assistants"[All Fields]	56,879
#18	Healthcare aides	("delivery of health care"[MeSH Terms] OR ("delivery"[All Fields] AND "health"[All Fields] AND "care"[All Fields]) OR "delivery of health care"[All Fields] OR "healthcare"[All Fields] OR "healthcare s"[All Fields] OR "healthcares"[All Fields]) AND "aides"[All Fields]	1,248
#19	Nursing assistants	"nursing assistants"[MeSH Terms] OR ("nursing"[All Fields] AND "assistants"[All Fields]) OR "nursing assistants"[All Fields]	8,416
#20	Nursing aides	("nursing"[MeSH Terms] OR "nursing"[All Fields] OR "nursings"[All Fields]) AND "aides"[All Fields]	1,843
#21	Formal caregivers	("formal"[All Fields] OR "formalized"[All Fields]) AND ("caregiver s"[All Fields] OR "caregivers"[MeSH Terms] OR "caregivers"[All Fields] OR "caregiver"[All Fields] OR "caregiving"[All Fields])	2,921
#22	Combination:	<b>#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21</b>	526,064

PubMed	Search block: Frailty (I)		19. Jan 2022
Search #	Query	Search string	Results
#23	Frail	"frail"[All Fields] OR "frails"[All Fields] OR "frailty"[MeSH Terms] OR "frailty"[All Fields] OR "frailness"[All Fields]	34,147

PubMed	Search block: Long-term care (C)		19. Jan 2022
Search #	Query	Search string	Results
#24	Long-term care	"long term care"[MeSH Terms] OR ("long term"[All Fields] AND "care"[All Fields]) OR "long term care"[All Fields] OR ("long"[All Fields] AND "term"[All Fields] AND "care"[All Fields]) OR "long term care"[All Fields]	158,645
#25	Primary care	"primary health care"[MeSH Terms] OR ("primary"[All Fields] AND "health"[All Fields] AND "care"[All Fields]) OR "primary health care"[All Fields] OR ("primary"[All Fields] AND "care"[All Fields]) OR "primary care"[All Fields]	519,348
#26	Community healthcare	"community health services"[MeSH Terms] OR ("community"[All Fields] AND "health"[All Fields] AND "services"[All Fields]) OR "community health services"[All Fields] OR ("community"[All Fields] AND "healthcare"[All Fields]) OR "community healthcare"[All Fields]	453,397
#27	Community dwelling	"independent living"[MeSH Terms] OR ("independent"[All Fields] AND "living"[All Fields]) OR "independent living"[All Fields] OR ("community"[All Fields] AND "dwelling"[All Fields]) OR "community dwelling"[All Fields]	55,793
#28	Community nursing	("community"[All Fields] AND "nursing"[All Fields]) OR "community nursing"[All Fields]	85,995
#29	Home healthcare	("home environment"[MeSH Terms] OR ("home"[All Fields] AND "environment"[All Fields]) OR "home environment"[All Fields] OR "home"[All Fields] AND ("delivery of health care"[MeSH Terms] OR ("delivery"[All Fields] AND "health"[All Fields] AND "care"[All Fields]) OR "delivery of health care"[All Fields] OR "healthcare"[All Fields] OR "healthcare s"[All Fields] OR "healthcares"[All Fields])	68,971
#30	Home nursing	"home nursing"[MeSH Terms] OR ("home"[All Fields] AND "nursing"[All Fields]) OR "home nursing"[All Fields]	72,058

#31	Nursing home	"nursing homes"[MeSH Terms] OR ("nursing"[All Fields] AND "homes"[All Fields]) OR "nursing homes"[All Fields] OR ("nursing"[All Fields] AND "home"[All Fields]) OR "nursing home"[All Fields]	99,292
#32	Combination:	<b>#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR 30 OR #31</b>	1,155,165

PubMed	Combination of blocks		19. Jan 2022
Search #	Query	Search string	Results
#33	Combination (P):	<b>#4 OR #14 OR #22</b>	8,752,419
#34	Combination (PIC):	<b>#23 AND #32 AND #33</b>	11,877

For peer review only